Non-canonical autophagy in dendritic cells restricts cross-presentation and anti-tumor immunity

Payel Sil[1], Fei Zhao[1], Ginger W. Muse[1], Sing-Wai Wong[1], Joseph P. Kolb[1], Laura Miller DeGraff[1], Charles J. Tucker[2], Erica Scappini[2], Annelise G. Snyder[3], Sara Grimm[4], Andrew Oberst[3], and Jennifer Martinez[1,5]

[1]Immunity, Inflammation, and Disease Laboratory, National Institute of Environmental Health Sciences (NIEHS), National Institutes of Health (NIH), Research Triangle Park, NC 27709, USA
[2]Signal Transduction Laboratory, Fluorescence Microscopy, and Imaging Center, National Institute of Environmental Health Sciences (NIEHS), National Institutes of Health (NIH), Research Triangle Park, NC 27709, USA
[3]Department of Immunology, University of Washington, Seattle, WA 98109, USA.
[4]Division of Intramural Research, National Institute of Environmental Health Sciences (NIEHS), National Institutes of Health (NIH), Research Triangle Park, NC 27709, USA
[5]Corresponding Author
*Correspondence:
Jennifer Martinez, PhD
111 TW Alexander Dr., Rall Building, Room D248A
Research Triangle Park, NC 27709
USA
Phone: (984) 287-4089
Email: jennifer.martinez3@nih.gov

Keywords: autophagy, Rubicon, LC3-associated phagocytosis, cross-presentation, inflammation

Summary

Major Histocompatibility Complex I (MHC-I) molecules classically present peptides derived from endogenous antigens, but exogenous antigens can also gain access to the MHC-I machinery in dendritic cells (DCs), which can activate antigen-specific $CD8^+$ T cells. This process, termed cross-presentation, can be triggered by the uptake of dying autologous cells, including tumor cells, by DCs. The molecular mechanisms that underlie efficient cross-presentation remain largely uncharacterized, and an improved understanding of these mechanisms might reveal novel strategies for anti-tumor therapies. Rubicon (RUBCN) is a molecule required for LC3-associated phagocytosis (LAP), but dispensable for canonical autophagy, and mice lacking this protein develop an autoimmune inflammatory pathology with age. Here, we demonstrate that *Rubcn*-deficient DCs have increased retention of engulfed cellular cargo in immature phagosomes resulting in increased phagosome-to-cytosol escape and antigen access to proteasome-mediated degradation. As a result, mice selectively lacking *Rubcn* in DCs mount stronger tumor antigen-specific $CD8^+$ T cell responses and exhibit decreased tumor burden compared to wild type littermates. These findings identify LAP as a key regulator of cross-presentation and suggest that targeting RUBCN might represent a novel strategy for anti-tumor therapy.

Introduction

The ability of the immune system to distinguish between self and non-self is integral to maintaining homeostasis and eradicating exogenous threats. Antigen-presenting cells (APCs), specifically DCs, educate the host's adaptive immune response in a controlled and antigen-specific manner. $CD8^+$ T cells are activated by peptides generated from intracellular antigens and presented in the context of MHC-I. Peptides derived from healthy self-antigens presented to $CD8^+$ T cells in the periphery elicit a minimal or absent response, as $CD8^+$ T cells expressing T cell receptors (TCRs) that recognize self-antigens undergo negative selection in the thymus prior to their population of the periphery (Rock et al., 2016). However, when cells are infected by virus or are transformed by an oncogene, they can produce proteins that are not considered self, such as virus-encoded proteins, and the presentation of these aberrant antigens via MHC-I activates a robust $CD8^+$ T cell response (Hansen and Bouvier, 2009). Therefore, the MHC-I pathway represents an evolutionarily conserved mechanism that serves as a quality control mechanism for endogenous proteins and viral defense (Kaufman, 2018).

As the activation of $CD8^+$ T cells is largely limited to their localization within secondary lymphoid tissues, they must rely on the migration of patrolling APCs to deliver antigens to them (Hansen and Bouvier, 2009). Classically, exogenous antigens are sensed as foreign, phagocytosed, processed by the endosomal-lysosomal network, and loaded onto MHC-II molecules to stimulate antigen-specific activation of $CD4^+$ T cells (Rock et al., 2016). Cross-presentation is a mechanism by which DCs can traffic exogenous antigens, such as autologous dying cells, acquired during surveillance to the MHC-I pathway for the activation of the $CD8^+$ T cell response (Cruz et al., 2017). Specific subsets of DCs, such as $CD8\alpha^+$ DCs, are the primary executors of cross-presentation (Pooley et al., 2001), as they retain phagocytosed material in less degradative compartments for longer periods than other phagocytes, allowing for limited proteolysis and prolonged preservation of antigen integrity (Belizaire and Unanue, 2009). Macrophages, for

example, quickly degrade intraphagosomal cargo via efficient maturation of the endocytic compartments, therefore limiting their cross-presentation capacity (Savina and Amigorena, 2007). Cross-presentation is specifically critical for the immunologically mediated clearance of tumors, and mice deficient in cross-presentation fail to generate a tumor-specific $CD8^+$ T cell response and display significantly increased tumor burden (Cruz et al., 2017; Fehres et al., 2014; Huang et al., 1994; Wolfers et al., 2001). Thus, the efficacy of MHC-I to mediate delivery of both self-made and exogenously acquired antigens to $CD8^+$ T cells highlights the importance of cytotoxic T cell activity in mitigating a multitude of pathological threats.

Exogenous antigens can access the MHC-I machinery via two pathways – the cytosolic pathway or the vacuolar pathway. In the cytosolic pathway, internalized cargo can escape the phagosome and enters the cytosol, wherein it is subjected to proteasome-mediated degradation into peptides. These peptides can then be transported to the ER by transporter associated with antigen processing (TAP1/2), where further processing by ER aminopeptidase 1 (ERAP1) and eventual loading onto the MHC-I molecule occurs. Peptide-MHC-I complexes are then transported to the Golgi apparatus and shuttled to the plasma membrane. In the vacuolar pathway, however, peptide generation, processing, and loading onto MHC-I molecules occurs exclusively within endocytic compartments in a proteasome- and TAP1-independent manner (Cruz et al., 2017; Fehres et al., 2014; Joffre et al., 2012).

Recent work has highlighted the activity and phagosomal trafficking of Sec22b protein during both the cytosolic and vacuolar pathways of cross-presentation, and the absence of Sec22b results in compromised cross-presentation (Alloatti et al., 2017; Cebrian et al., 2011). In DCs, Sec22b translocates to the cargo-containing phagosome and regulates the transport of ER and ER-Golgi intermediate compartment (ERGIC) proteins to the phagosome. Mechanistically, Sec22b-mediated recruitment of ERGIC proteins promotes the export of intraphagosomal cargo to the

cytosol and delays maturation of the cargo-containing phagosome (Alloatti et al., 2017; Cebrian et al., 2011). In some cases, proteasome-generated peptides can be re-introduced to the phagosome via Sec22b-mediated delivery of ERGIC proteins, like TAP1/2, and signaling via Toll-like receptors (TLRs) during cross-presentation can facilitate the translocation of MHC-I to the phagosome, where the peptide-MHC-I complexes are assembled and transported to the plasma membrane independent of the Golgi apparatus (Nair-Gupta et al., 2014).

Despite recent advances in our understanding of cross-presentation, neither the relative contributions of each pathway nor the signals that mediate the recruitment and activity of key components are fully understood. We and others have described a unique form of non-canonical autophagy that couples phagocytosis to the autophagy machinery, termed LAP (Martinez et al., 2011a; Sanjuan et al., 2009). LAP, but not canonical autophagy, requires the activity of Rubicon (RUBCN), a protein that binds and regulates both the Class III PI3K complex and the NOX2 complex, both of which are essential for LAP (Martinez et al., 2015). Cargo-containing phagosomes are decorated with lipidated LC3 to form the LAPosome, which can then fuse to lysosomes for proper processing and degradation of the phagocytosed material (Martinez et al., 2011a). *In vitro* studies reveal that *Rubcn*$^{-/-}$ macrophages phagocytose normally, but fail to translocate LC3-II to the phagosome. This defect results in cargo persisting in immature phagosomal compartments and increased production of pro-inflammatory mediators, such as IL-6 and IL-12 (Martinez et al., 2011a; Martinez et al., 2016b). As one of the most ubiquitous sources for cross-presented antigens is dying cells and engulfment of dying cells during efferocytosis is a trigger for LAP, we hypothesized that LAP played a role in regulating cross-presentation.

Rubcn$^{-/-}$ mice are a valuable tool to allow the study of LAP-dependent mechanisms and pathologies without confounding deficits in the canonical autophagy pathway (Martinez et al., 2016b; Martinez et al., 2015). Broadly, LAP is a regulator of immunotolerance during the

clearance of dying cells (efferocytosis), and *Rubcn*$^{-/-}$ mice develop systemic lupus erythematosus (SLE)-like autoimmunity and autoinflammation with age, which is associated with defective processing of dying cells (Martinez et al., 2016b). Interestingly, aged *Rubcn*$^{-/-}$ mice exhibit increased levels of activated CD8^{+} T cells in their periphery, suggesting that LAP deficiency could confer an increased capacity for MHC-I cross-presentation (Cunha et al., 2018; Martinez et al., 2016b). Here, we show, both *in vivo* and *in vitro*, that *Rubcn*$^{-/-}$ DCs can cross-present antigens more efficiently than wild type DCs, resulting in increased CD8^{+} T cell proliferation and activation. We also demonstrate that the engulfed cargo persists within less degradative phagosomes in the absence of RUBCN. These phagosomes are enriched for RAB5A and Sec22b, and phagosome-to-cytosol escape is significantly increased in *Rubcn*$^{-/-}$ DCs, compared to wild type DCs. This increased capacity for cross-presentation translates into a more robust CD8^{+} T cell response to tumor antigens and decreased tumor burden. Taken together, we have identified LAP as a key mechanism that regulates cross-presentation in DCs, emphasizing its importance in maintaining homeostasis and limiting immune activation.

Results

Rubcn$^{-/-}$ DCs display enhanced cross-presentation capacity.

To explore the role of LAP in cross-presentation, we generated bone-marrow derived DCs using recombinant Flt3L from both *Rubcn*$^{+/+}$ and *Rubcn*$^{-/-}$ mice (Brasel et al., 2000) (**Figure S1A-B**). On day 6-8, DCs was analyzed by FACS analysis, and cultures over 75% CD11c^{+} CD103^{+} CD8α^{+} were used for *in vitro* experiments. Upon co-culture with apoptotic B16 melanoma cells expressing membrane bound ovalbumin (B16-OVA), *Rubcn*$^{-/-}$ DCs had significantly increased levels of the $OVA_{257-264}$ peptide (SIINFEKL) presented in the context of MHC-I (H2-K^{b}-$OVA_{257-264}$) in a dose-dependent manner, compared to *Rubcn*$^{+/+}$ DCs (**Figure 1A**). This increase was dependent on phagocytosis, as upregulation of H2-K^{b}-$OVA_{257-264}$ expression was abolished when co-culture was performed at 4°C (**Figure S1C**). Increased expression of H2-K^{b}-$OVA_{257-264}$ in

178 *Rubcn*$^{-/-}$ DCs was not due to an increase in total H2-K^{b} (MHC-I), as both *Rubcn*$^{+/+}$ and *Rubcn*$^{-/-}$
179 DCs increased total H2-K^{b} expression equivalently and in a phagocytosis-dependent manner
180 (**Figure 1B, Figure S1C**). While studies have demonstrated that DCs deficient for *Atg5* or *Atg7*
181 exhibit reduced recycling of MHC-I molecules, resulting in increased MHC-I antigen presentation
182 (Loi et al., 2016), our data suggests that *Rubcn*-deficiency has no effect on total MHC-I
183 expression, but rather enhances cross-presentation specifically. Transcriptional analysis via
184 RNA-seq revealed that upon co-culture with apoptotic Jurkat cells, *Rubcn*$^{-/-}$ DCs upregulated
185 components of cross-presentation (such as *Canx*, *Ciita*, and *Erap1*) and activation machinery
186 (such as *CD40* and *CD86*), more robustly than *Rubcn*$^{+/+}$ DCs (**Figure 1C).** Similar to flow
187 cytometric analysis, *H2k1* expression was equivalent in *Rubcn*$^{+/+}$ and *Rubcn*$^{-/-}$ DCs (**Figure 1C**).
188 We used qPCR to confirm an upregulation of transcriptional activity at 6 hours post-stimulation
189 and observed that *Rubcn*$^{-/-}$ DCs displayed increased expression of *Tap1*, *Tap2*, and *B2m*,
190 compared to *Rubcn*$^{+/+}$ DCs **(Figure S1D**). While *Rubcn*$^{+/+}$ and *Rubcn*$^{-/-}$ DCs had equivalent levels
191 basally, *Rubcn*$^{-/-}$ DCs displayed increased surface expression of CD86, a co-stimulatory molecule
192 (Greenwald et al., 2005), in response to co-culture with apoptotic B16-OVA cells (**Figure 1D**). In
193 addition, and similar to *Rubcn*$^{-/-}$ macrophages, *Rubcn*$^{-/-}$ DCs significantly upregulated pro-
194 inflammatory cytokines and chemokines, compared to *Rubcn*$^{+/+}$ DCs (Martinez et al., 2011a;
195 Martinez et al., 2016b). Specifically, *Rubcn*$^{-/-}$ DCs upregulated factors known to promote CD8^{+} T
196 cell recruitment (such as *Ccl2*, *Ccl3*, *Ccl4*, *Cxcl9*, and *Cxcl10*) and activation (such as *Il1b*, *Il6*,
197 *Il12b*, and *Tnf*) (**Figure 1C, S1E**) (Rahimi and Luster, 2018; Turner et al., 2014). Consistent with
198 previous reports (Hayashi et al., 2018), *Rubcn*$^{-/-}$ DCs produced less IFNβ than *Rubcn*$^{+/+}$ DCs
199 (**Figure 1C, S1E**). Therefore, *Rubcn*$^{-/-}$ DCs significantly upregulate key mediators known to
200 promote an inflammatory response and enhance CD8^{+} T cell activation.
201
202 A recent study identified a process akin to LAP, called LC3-associated endocytosis (LANDO),
203 wherein uptake of particles during receptor-mediated endocytosis (RME) results in Rubcn-

dependent LC3-decorated, cargo-containing endosomes (Heckmann et al., 2019). Therefore, we also examined the ability to *Rubcn*$^{+/+}$ and *Rubcn*$^{-/-}$ DCs to upregulate cross-presentation in response to endocytosis of soluble ovalbumin protein (sOVA protein), a well-characterized *in vitro* model antigen for cross-presentation (Blachere et al., 2005; Burgdorf et al., 2006; Cebrian et al., 2011; Yatim et al., 2015). Similar to apoptotic B16-OVA cell co-culture, endocytosis of sOVA protein induces significantly increased expression of H2-K^{b}-OVA$_{257-264}$ by *Rubcn*$^{-/-}$ DCs, compared to *Rubcn*$^{+/+}$ DCs (**Figure S1F**). Importantly, both *Rubcn*$^{+/+}$ and *Rubcn*$^{-/-}$ DCs upregulated H2-K^{b}-OVA$_{257-264}$ expression at equivalent levels in response to stimulation with OVA$_{257-264}$ peptide, indicating that cross-presentation, but not classical MHC-I antigen presentation, was increased in the absence of *Rubcn* (**Figure S1F**).

To test their capacity to activate CD8^{+} T cells, *Rubcn*$^{+/+}$ and *Rubcn*$^{-/-}$ DCs were loaded with apoptotic B16-OVA cells, followed by co-culture with naïve CD8^{+} T cells from OT-I mice, which express a transgenic T cell receptor that recognizes the OVA$_{257-264}$ peptide in the context of MHC-I (Hogquist et al., 1994). OT-I T cells were labeled with Tag-it Proliferation Dye prior to the co-culture, and proliferation and activation were assessed 48 hours later. Co-culture with *Rubcn*$^{+/+}$ DCs resulted in a modest amount of proliferation of OT-I T cells. Consistent with higher levels of cross-presentation machinery, co-culture with *Rubcn*$^{-/-}$ DCs resulted in a more robust proliferation of OT-I T cells (**Figure 1E**). OT-I T cells co-cultured with *Rubcn*$^{-/-}$ DCs also demonstrated increased effector function, as evidenced by increased IFNγ production (**Figure 1F**). Similarly, OT-I T cells co-cultured with sOVA protein-loaded *Rubcn*$^{-/-}$ DCs also demonstrated increased proliferation and effector function. No difference was in proliferation or activation was observed in OT-I T cells co-cultured with OVA$_{257-264}$ peptide -loaded *Rubcn*$^{+/+}$ or *Rubcn*$^{-/-}$ DCs (**Figure S1G-H**).

Both increased CD86 expression and pro-inflammatory cytokine/chemokine production can positively contribute to $CD8^+$ T cell activation (Zhang and Bevan, 2011). To determine if increased CD86 expression on *Rubcn*$^{-/-}$ DCs was responsible for increased $CD8^+$ T cell activation capacity, we performed OT-I : DC co-cultures in the presence of anti-CD86 blocking antibody or isotype control antibody. Isotype control antibody treatment had no effect on OT-I proliferation, while the higher dose (10 μg/ml) of anti-CD86 blocking antibody inhibited OT-I proliferation modestly with both *Rubcn*$^{+/+}$ and *Rubcn*$^{-/-}$ DCs (**Figure 1G**). However, OT-I proliferation in culture with *Rubcn*$^{-/-}$ DCs with anti-CD86 inhibition was still significantly increased compared OT-I proliferation in culture with wild type DCs with anti-CD86 inhibition (**Figure 1G, S2A**). To assess the role of pro-inflammatory cytokine/chemokines produced by *Rubcn*$^{-/-}$ DCs, we collected culture media from *Rubcn*$^{+/+}$ and *Rubcn*$^{-/-}$ DCs after 24 hours of culture with apoptotic B16-OVA cells. This conditioned media was then used in new OT-I : DC co-cultures stimulated with apoptotic B16-OVA cells. The presence of *Rubcn*$^{-/-}$ (KO) conditioned media in OT-I: *Rubcn*$^{+/+}$ DC cultures did not confer a proliferative advantage, and the presence of *Rubcn*$^{+/+}$ (WT) conditioned media did not inhibit proliferation of OT-I co-cultured with *Rubcn*$^{-/-}$ DCs (**Figure 1H, S2B**). Additionally, anti-CD86 inhibition had no effect on OT-I proliferation in conditioned media co-cultures (**Figure 1H, S2B**). Therefore, increased cross-presentation capacity, not increased co-stimulation or inflammatory cytokine/chemokine production, is the main contributing factor to increased antigen presentation capacity of *Rubcn*$^{-/-}$ DCs.

Although multiple molecular components overlap between canonical autophagy and LAP (and LANDO), only canonical autophagy requires the activity of the pre-initiation complex, composed of ATG13, FIP200, and ULK1 (Martinez et al., 2011a). We and others have reported that *Rubcn* deficiency can result in increased canonical autophagic activity (Martinez et al., 2015). To confirm that RUBCN's effect on cross-presentation occurs independently of canonical autophagy, we examined the cross-presentation capacity of *Ulk1*$^{+/+}$ and *Ulk1*$^{-/-}$ DCs. *Ulk1*$^{+/+}$ and *Ulk1*$^{-/-}$ DCs

displayed equivalent expression levels of H2-K^b-$OVA_{257-264}$ upon stimulation with either sOVA protein or apoptotic B16-OVA cells (**Figure S2C**). As such, OT-I T cells co-cultured with either *Ulk1*$^{+/+}$ and *Ulk1*$^{-/-}$ DCs proliferated similarly (**Figure S2D**), indicating that defects in LAP, not canonical autophagy, is responsible for increased cross-presentation in *Rubcn*$^{-/-}$ DCs. We further confirmed this finding with DCs deficient for *Atg7* from *Cd11c-Cre Atg7*$^{flox/flox}$ mice, which contain DCs deficient for both canonical autophagy and LAP (Martinez et al., 2011a; Sanjuan et al., 2009). *Atg7*-deficient DCs also display increased cross-presentation capacity as evidenced by increased expression of H2-K^b-$OVA_{257-264}$ (**Figure S2E**) and increased OT-I T cell proliferation in co-culture (**Figure S2F**). Collectively, these data demonstrate that LAP- and LANDO-deficiency confer increased cross-presentation capacity.

***Rubcn*$^{-/-}$ DCs engulf cargo, yet retain cargo in less degradative phagosomes.** To address how the absence of LAP imparts an increased capacity for cross-presentation, we next examined the nature of the cargo-containing phagosome in the absence of *Rubcn*. *Rubcn*$^{+/+}$ and *Rubcn*$^{-/-}$ DCs phagocytosed apoptotic cells (**Figure 2A**) equivalently, so we utilized flow cytometry to analyze LC3 localization on cargo-containing phagosomal membranes. Briefly, apoptotic B16-OVA cells were labeled with PKH26 and co-cultured with *Rubcn*$^{+/+}$ and *Rubcn*$^{-/-}$ DCs that express the transgene for GFP-LC3 (Martinez et al., 2015). After four hours, DCs were harvested, permeabilized on ice with digitonin (20 µg/ml), which disrupts the plasma membrane, but leaves intracellular membranes intact (Martinez et al., 2015). GFP-LC3 translocation to the PKH26$^+$ apoptotic cell-containing phagosome was analyzed via flow cytometry by examining mean fluorescent intensity (MFI) of GFP-LC3 associated with PKH26$^+$ events (Shvets and Elazar, 2009). While *Rubcn*$^{+/+}$ DCs translocated GFP-LC3 to apoptotic cell-containing phagosomes, *Rubcn*$^{-/-}$ DCs contained significantly reduced GFP-LC3 association with apoptotic cell-containing phagosomes (**Figure 2B**).

Compared to macrophages, DCs are considered more efficient at cross-presentation, as they retain engulfed cargo in less acidified compartments, allowing for longer periods of antigen integrity (Belizaire and Unanue, 2009). To explore the nature of cargo-containing phagosomes in *Rubcn*$^{-/-}$ DCs, we utilized latex beads coated with OVA protein and performed immunofluorescence for localization of RAB5A, a marker of early endosomes, and LAMP2, a marker of lysosomes (Henault et al., 2012). Unstimulated *Rubcn*$^{+/+}$ and *Rubcn*$^{-/-}$ DCs exhibited equivalent RAB5A and LAMP2 staining (**Figure 2C**), and both genotypes displayed equivalent levels of lysosomal enzymes, including Cathepsin S (*Ctss*) which has been shown to be critical for cross-presentation (Shen et al., 2004), suggesting no inherent lysosomal defect in *Rubcn*$^{-/-}$ DCs (**Figure S3A**). However, LAMP2 robustly translocated to OVA-bead-containing phagosomes in *Rubcn*$^{+/+}$ DCs, but failed to localize with OVA-bead-containing phagosomes in *Rubcn*$^{-/-}$ DCs (**Figure 2C**). Rather, RAB5A localized with OVA-bead-containing phagosomes in *Rubcn*$^{-/-}$ DCs, indicative of their relative immaturity (**Figure 2C**). We further examined the nature of cargo-containing phagosomes in *Rubcn*$^{-/-}$ DCs using apoptotic B16-OVA cells labeled with pHrodo Red (Jantas et al., 2015), a pH-sensitive dye that increases fluorescence in acidic environments, such as lysosomes. *Rubcn*$^{+/+}$ DCs exhibited significant pHrodo Red fluorescence when co-cultured with pHrodo-labeled apoptotic B16-OVA cells, yet *Rubcn*$^{-/-}$ DCs displayed minimal pHrodo Red fluorescence upon co-culture, consistent with their decreased LAMP2 localization at the cargo-containing phagosome (**Figure 2D**). We also observed a decreased capacity for clearance of apoptotic cells *in vitro* by *Rubcn*$^{-/-}$ DCs, consistent with retention of engulfed cargo in a less degradative environment (**Figure S3B**). Similar data were obtained using pHrodo-labeled sOVA protein, wherein *Rubcn*$^{-/-}$ DCs displayed minimal pHrodo Red fluorescence upon stimulation, suggesting that both LAP- and LANDO-deficiency results in defects in the maturation of cargo-containing vesicles (**Figure S3C**).

Recent studies suggest that the active translocation of ERGIC-associated proteins to the phagosome via a Sec22b-mediated mechanism is required for cross-presentation. It is believed that Sec22b functions by both promoting phagosome-to-cytosol escape of the cargo, as well as inhibiting phagosomal-lysosomal maturation (Cebrian et al., 2011; Wu et al., 2017). *Rubcn*$^{+/+}$ and *Rubcn*$^{-/-}$ DCs displayed equivalent localization of Sec22b with the ERGIC marker, Calreticulin, at a resting state (**Figure 2E, Figure S3D**). In the absence of *Rubcn*, however, Sec22b co-localization with OVA-bead-containing phagosomes was significantly increased, compared to wild type DCs (**Figure 2E-F**). Taken together, these data demonstrate that *Rubcn* deficiency results in retention of phagocytosed material in immature phagosomal compartments with increased association of the pro-cross-presentation molecule, Sec22b.

Rubcn$^{-/-}$ DCs exhibit increased phagosome-to-cytosol escape and proteasome-mediated generation of peptides.

To examine phagosomal escape, we utilized two different approaches. In the first assay (Cebrian et al., 2011; Keller et al., 2013), *Rubcn*$^{+/+}$ and *Rubcn*$^{-/-}$ DCs were loaded with the cephalosporin derived FRET substrate, CCF4, which accumulates in the cytosol and emits a FRET signal at 535 nm. Apoptotic B16-OVA cells were added to the CCF4-loaded DCs in the absence or presence of β-lactamase at 4°C or 37°C. Upon export to the cytosol, β-lactamase cleaves CCF4, resulting in a reduced 535 nm FRET signal and increased emission at 450 nm (Loi et al., 2016). Flow cytometry was used to measure the ratiometric values between both signals (450 nm : 535 nm, as a ratio of cleaved CCF4 to uncleaved CCF4) as a means of examining β-lactamase export to the cytosol (Loi et al., 2016). As demonstrated by increased ratio values, *Rubcn*$^{-/-}$ DCs exhibited increased cleaved CCF4 fluorescent signal (and a decrease in uncleaved CCF4 signal), upon co-culture with apoptotic B16-OVA cells at both 90 and 180 minutes, compared to *Rubcn*$^{+/+}$ DCs

(**Figure 3A-B**). This increase in escape was dependent on phagocytosis, as cells cultured at 4°C displayed minimal cleaved CCF4 fluorescent signal (**Figure 3A-B**).

Additionally, we incubated *Rubcn*$^{+/+}$ and *Rubcn*$^{-/-}$ DCs with PKH26-labeled apoptotic B16-OVA cells, and after 4 hours, DCs were treated with a concentration of digitonin mild enough to permeabilize the plasma membrane but leave phagosomal membranes intact (Martinez et al., 2015; Repnik et al., 2016). To confirm that the mild digitonin dose (20 μg/ml) was not permeabilizing lysosomal membranes, we incubated permeabilized cell extracts with the cathepsin-specific fluorogenic substrate, Z-FR-AMC, which emits fluorescence at 460 nm upon cathepsin-mediated cleavage (Repnik et al., 2016). Permeabilization with 20 μg/ml digitonin did not results in a fluorescent signal, indicative of no cathepsin release from lysosomes (**Figure S3E**). Permeabilization with a higher dose (200 μg/ml) of digitonin, however, resulted in increased cathepsin-mediated fluorescence in both *Rubcn*$^{+/+}$ and *Rubcn*$^{-/-}$ DCs, suggesting that increased concentrations of digitonin are capable of permeabilizing the membranes of intracellular structures (**Figure S3E**). Importantly, *Rubcn*$^{+/+}$ and *Rubcn*$^{-/-}$ DCs displayed equivalent levels of cathepsin-mediated fluorescence at 200 μg/ml digitonin, and transcriptional analysis revealed no difference in total cathepsin content (**Figure S3A, S3E**). Compared to *Rubcn*$^{+/+}$ DCs, *Rubcn*$^{-/-}$ DCs displayed significantly increased phagosomal escape of apoptotic B16-OVA cells, as evidenced by increased PKH26^{+} fluorescence in cytosolic extracts of DCs permeabilized with 20 μg/ml digitonin (**Figure S3F**). Similar results were obtained when *Rubcn*$^{+/+}$ and *Rubcn*$^{-/-}$ DCs were cultured with Alexa Fluor 555-conjugated sOVA protein (**Figure S3G**). Taken together, these data demonstrate the RUBCN limits phagosome-to-cytosol antigen escape during LAP (and LANDO).

We next asked if cargo persisting in immature phagosomal compartments contributed to enhanced phagosomal escape. Chloroquine (CQ) is a lysosomotropic weak base widely used as

a pharmacological inhibitor of autophagic flux and LAP (Martinez et al., 2011a; Mauthe et al., 2018). Recent studies demonstrate that while other autophagy inhibitors, such as bafilomycin A, inhibit autophagy by increasing the lysosomal pH of autolysosomes, CQ functions by inhibiting autophagosome and lysosome fusion, without modulating lysosomal acidity (Boya et al., 2003; Mauthe et al., 2018). Pre-treatment of *Rubcn*$^{+/+}$, but not *Rubcn*$^{-/-}$, DCs resulted in increased phagosomal escape of apoptotic B16-OVA cells (**Figure S3F**) (or sOVA protein, **Figure S3G)**, in a dose-dependent manner, suggesting that retention of cargo in less degradative compartments can promote phagosomal escape. Similarly, *Rubcn*$^{+/+}$ DCs pre-treated with CQ exhibited significantly increased capacity for cross-presentation, as evidenced by higher levels of H2-K^{b}-OVA$_{257\text{-}264}$ expression in response apoptotic B16-OVA cells (**Figure 3C**), supporting the notion that inhibition of phagosomal-lysosomal fusion promotes cross-presentation. CQ treatment of *Rubcn*$^{-/-}$ DCs, however, had no effect on their cross-presentation ability. We observed similar results with sOVA protein-induced LANDO (**Figure S3H**), suggesting that defects in phagosomal maturation in LAP- or LANDO-deficient cells allows for increased phagosome-to-cytosol escape and hence, increased cross-presentation.

Increased escape of engulfed cargo from the phagosome to the cytosol suggests that antigens are now accessible to proteasome-mediated degradation. While it has been reported that peptide generation can occur in the phagosomal compartments, most data indicate that peptide generation occurs primarily via the proteasome pathway (Kovacsovics-Bankowski and Rock, 1995; Palmowski et al., 2006). To examine the contribution of the proteasome to increased cross-presentation in *Rubcn*$^{-/-}$ DCs, we pre-treated *Rubcn*$^{+/+}$ and *Rubcn*$^{-/-}$ DCs with MG-132, a potent cell-permeable proteasome inhibitor (Burgdorf et al., 2006), followed by co-culture with apoptotic B16-OVA cells. Cross-presentation by both *Rubcn*$^{+/+}$ and *Rubcn*$^{-/-}$ DCs was significantly impaired by proteasome inhibition by MG-132 in a dose-dependent manner, with a reduction in expression of H2-K^{b}-OVA$_{257\text{-}264}$ (**Figure 3D**). Pre-treatment with MG-132 also significantly inhibited cross-

presentation induced by sOVA protein in both genotypes (**Figure S3I**). Transcriptional analysis demonstrated that *Rubcn*$^{+/+}$ and *Rubcn*$^{-/-}$ DCs had equivalent expression levels of key proteasomal subunits, basally and upon apoptotic cell co-culture (**Figure S3J**). Collectively, our data reveal that, in the absence of *Rubcn*, prolonged retention of engulfed cargo within immature, Sec22b^{+} phagosomal compartments results in increased translocation of antigens from the phagosome to the cytosol and increased accessibility to degradation by the proteasome.

Cross-presentation by *Rubcn*$^{-/-}$ DCs requires ER/Golgi-mediated activity.

Classically, proteasome-generated peptides are loaded onto MHC-I molecules via TAP1/2 on the ER, where they can be further trimmed by ERAP1 to MHC-I-compatible lengths, if needed. The peptide-MHC-I complex (pMHC-I) is then trafficked to the plasma membrane via the Golgi apparatus (Cruz et al., 2017). Evidence exists, however, for TAP1-independent pathway, wherein proteasome-generated peptides re-enter the phagosome and are loaded onto MHC-I within the phagosome (Joffre et al., 2012; Nair-Gupta et al., 2014). Therefore, we examined whether TAP1 loading of peptides at the ER and trafficking of pMHC-I via the Golgi apparatus was required for cross-presentation in *Rubcn*$^{+/+}$ and *Rubcn*$^{-/-}$ DCs. Brefeldin A disrupts Golgi-ER-mediated protein transport by inhibiting the recruitment and activity of GBF1, a guanine nucleotide exchange factor (GEF) required for ADP-ribosylation factor (ARF)-mediated protein transport between the ER and the Golgi (Garcia-Mata et al., 2003). Brefeldin A has been shown to inhibit multiple trafficking pathways, including cross-presentation (Andrieu et al., 2003; Gutierrez-Martinez et al., 2015). Treatment of *Rubcn*$^{+/+}$ and *Rubcn*$^{-/-}$ DCs with Brefeldin A drastically reduced cross-presentation in response to apoptotic B16-OVA (**Figure 3E**) or sOVA protein (**Figure S3K**), suggesting ER/Golgi-mediated protein transport is required for cross-presentation. While peptide loading onto MHCI molecules can occur post-Golgi (Cruz et al., 2017; Joffre et al., 2012), the ability of Brefeldin A to inhibit cross-presentation, in conjunction with the upregulation of *Erap1* (**Figure 1C**) and *Tap1* (**Figure S1D**), suggests that the cytosolic pathway is the predominant process in our system.

408

409 ***Cd11c-Cre Rubcn$^{flox/flox}$* mice display decreased tumor burden.**

410

411 The ability to mount an effective anti-tumor response requires cross-presentation of cell-
412 associated antigens *in vivo* to elicit robust CD8$^+$ T cell activity (Alloatti et al., 2017). To investigate
413 the role of LAP in cross-presentation, we utilized mice harboring a DC-specific deletion of
414 the *Rubcn* gene (*Cd11c-Cre Rubcn$^{flox/flox}$*). As controls, we used littermates that expressed the
415 floxed *Rubcn* gene but did not express the Cre recombinase (*Rubcn$^{flox/flox}$*) (**Figure S4A**). B16-
416 OVA cells were injected intradermally into *Rubcn$^{flox/flox}$* and *Cd11c-Cre Rubcn$^{flox/flox}$* mice, and
417 tumor growth and intratumoral immune infiltration and activation were monitored. DC-specific
418 deletion of *Rubcn* resulted in significantly delayed tumor growth (**Figure 4A**) and significantly less
419 tumor burden (**Figure 4B, S4B**) *in vivo.* In addition, tumors from *Cd11c-Cre Rubcn$^{flox/flox}$* mice
420 contained more CD45^{neg} Zombie-UV$^+$ dead cells, compared to *Rubcn$^{flox/flox}$* mice, suggesting
421 increased tumor cell death (**Figure 4C**). As we observed an increase in the percentage of CD45$^+$
422 cells in the tumors of *Cd11c-Cre Rubcn$^{flox/flox}$* mice (**Figure 4D**), we next examined the immune
423 composition of the tumor (**Figure S4C**). On day 16, we observed that tumors from *Cd11c-Cre*
424 *Rubcn$^{flox/flox}$* mice contained more CD11c$^+$ CD103$^+$ CD8α^+ cross-presenting DCs than tumors from
425 *Rubcn$^{flox/flox}$* mice (**Figure 4E**). These *Rubcn*-deficient DCs also expressed significantly increased
426 levels of the tumor-derived OVA$_{257-264}$ peptide (SIINFEKL) presented in the context of MHC-I (H2-
427 K^b-OVA$_{257-264}$) (**Figure 4F**). No differences were detected in percentage or activation status of
428 tumor-associated macrophages from *Rubcn$^{flox/flox}$* and *Cd11c-Cre Rubcn$^{flox/flox}$* mice (**Figure S4D**).
429 Moreover, the dLNs from *Cd11c-Cre Rubcn$^{flox/flox}$* mice contained more cross-presenting DCs,
430 compared to *Rubcn$^{flox/flox}$* mice (**Figure 4G**).

431

432 We then examined the endogenous OVA-specific CD8$^+$ T cell response using MHC-I peptide
433 tetramers of SIINFEKL, referred hereafter as Tetramer (Snyder et al., 2019; Yatim et al., 2015).
434 Tumors from *Cd11c-Cre Rubcn$^{flox/flox}$* mice contained significantly more Tetramer$^+$ CD8$^+$ T cells,

indicating that *Rubcn*-deficient DCs are more efficient at cross-presentation of tumor-derived antigens (**Figure 4H**). These OVA-specific $CD8^+$ T cells were more activated, as evidenced by increased expression of CD69, and more functional, as evidenced by increased production of IFNγ, TNFα, and Perforin (**Figure 4I**). Similarly, dLNs from *Cd11c-Cre Rubcn*$^{flox/flox}$ mice also contained more $Tetramer^+$ $CD8^+$ T cells that displayed a more activated phenotype, compared to dLNs from *Rubcn*$^{flox/flox}$ mice (**Figure 4J**). These trends continued, wherein tumors from *Cd11c-Cre Rubcn*$^{flox/flox}$ mice contained DCs with increased expression of H2-K^b-$OVA_{257-264}$ (**Figure S4E**) and more activated $Tetramer^+$ $CD8^+$ T cells (**Figure S4F**) at day 22. Overall, these studies demonstrate that *Cd11c-Cre Rubcn*$^{flox/flox}$ mice are able to cross-present tumor antigens more efficiently and mount a more robust tumor-specific $CD8^+$ T cell response, resulting in reduced tumor burden.

Discussion

The most abundant source of antigen for cross-presentation is the host, as host cells undergo a continuous cycle of death and homeostatic clearance. In this regard, the MHC-I pathway serves as necessary quality control of the state of self, facilitating the presentation of both endogenous proteins and antigens derived from exogenously acquired dying cells during efferocytosis. Whereas presentation of peptides generated from healthy cells elicits only a modest $CD8^+$ T cell response (as these highly autoreactive T cells undergo negative selection in the thymus), presentation of peptides from cells undergoing stress, such as transformation or viral infection, can result in a robust $CD8^+$ T cell response (Cruz et al., 2017). Efficient activation of $CD8^+$ T cells via cross-presentation, however, can be a double-edged sword. Defects in cross-presentation results in decreased anti-tumor responses and increased tumor burden (Alloatti et al., 2017). Conversely, heightened cross-presentation is associated with increased autoimmunity, as self-antigens are presented to and activate $CD8^+$ T cells more readily (Calderon and Unanue, 2012;

460 Ji et al., 2013). Thus, control of the cross-presentation pathway is a critical node in preserving the
461 balance between homeostasis and inflammation.
462
463 Here, we demonstrate that a form of non-canonical autophagy, LAP, and its related process,
464 LANDO, function to restrict cross-presentation in DCs. Mechanistically, we describe that LAP
465 functions as a negative regulator of cross-presentation by promoting the maturation of the cargo-
466 containing phagosome to limit phagosome-to-cytosol escape and antigen access to the
467 proteasome. In the absence of *Rubcn*, which is required for LAP but not canonical autophagy,
468 phagosomal maturation is significantly blunted, as LC3-II fails to decorate the phagosome to
469 promote fusion with the lysosome. Within *Rubcn*$^{-/-}$ DCs, cargo persists in immature vesicles,
470 which also display increased association of Sec22b, a pro-cross-presentation molecule. This
471 results in increased phagosome-to-cytosol antigen escape, subsequent processing of antigen into
472 peptides, and heightened presentation of pMHC-I on the plasma membrane via ER/Golgi activity.
473
474 Recent studies have demonstrated a role for ATG5 in MHC-II-mediated antigen presentation
475 during experimental autoimmune encephalomyelitis, wherein CD4^{+} T cell activation was reduced
476 in *Cd11c-Cre*$^{+}$ *Atg5*$^{flox/flox}$ mice (Keller et al., 2017). This suggests that LAP is required for MHC-
477 II antigen presentation, though studies examining *Rubcn's* role in MHC-II antigen presentation
478 are needed. While other studies have implicated macroautophagy (via ATG5 and ATG7) in the
479 recycling of MHC-I molecules (Loi et al., 2016), we did not observe an increase in total MHC-I
480 (H2-K^{b}) expression in *Rubcn*$^{-/-}$ DCs at the transcriptional or protein level. As RUBCN can also
481 inhibit canonical autophagy (Martinez et al., 2015), it is possible that increased autophagy
482 conferred by the absence of *Rubcn* accounts for this difference in observations, suggesting that
483 further studies detailing the crosstalk between these two related pathways during cross-
484 presentation are needed.
485

Phagosomes from *Rubcn*$^{-/-}$ DCs exhibit increased Sec22b association, which serves two pro-cross-presentation purposes. Firstly, Sec22b plays a role in inhibiting phagosomal maturation. Secondly, Sec22b also promotes escape of engulfed cargo from the phagosome to the cytosol, where it is vulnerable to proteasome-mediated processing into peptides (Alloatti et al., 2017; Cebrian et al., 2011). The mechanisms by which RUBCN regulates Sec22b association with the phagosome is an outstanding question, though. It is predicted that Sec22b can directly interact with RAB5A, which is a classical marker of endosomes and immature phagosomes (Rouillard et al., 2016). Our data demonstrate that engulfed cargo persists in RAB5A^{+} phagosomes in the absence of RUBCN, suggesting that Sec22b co-localization could be due to increased RAB5A presence. Therefore, our data demonstrate that RUBCN employs multiple strategies to limit cross-presentation and subsequent autoreactivity.

Selective inhibition of endosome-associated TAP1 results in inhibition of cross-presentation induced by high doses of sOVA protein, suggesting that ER/Golgi-mediated trafficking of pMHC-I is not required for cross-presentation in this scenario (Burgdorf et al., 2008). However, this study also demonstrated that TLR4/MyD88-mediated translocation of TAP1 to endosomes was not required for efficient cross-presentation of sOVA protein at a dose (200 μg/ml) roughly equivalent to the dose used in our study (150 μg/ml), suggesting that cargo can enter the cross-presentation pathway at different points (Burgdorf et al., 2008). Inhibiting ERAP1, the ER enzyme responsible for trimming peptides into an MHC-I suitable form, or IRAP1, its endosomally localized relative, each reduces cross-presentation by approximately half, with silencing both conferring an additive effect (Saveanu et al., 2009). As *Rubcn*$^{-/-}$ DCs demonstrated increased expression of *Tap1* and *Erap1* (but not in *Irap1*), as well as exhibited decreased cross-presentation capacity in response to Brefeldin A treatment, we hypothesize that *Rubcn*-deficiency promotes cross-presentation via

510 TAP1-dependent, ER/Golgi-mediated activity. Further studies using tools that inhibit TAP1 at the
511 ER or phagosome are required to further define these molecular mechanisms.
512
513 In addition to the uptake of dying cells, viruses can trigger cross-presentation. While some
514 viruses, such as human immunodeficiency virus (HIV), are cross-presented in a proteasome- and
515 TAP-dependent manner (Maranon et al., 2004), other viruses, such as influenza A virus (IAV) and
516 hepatitis B virus (HBV), have been reported to utilize the vacuolar pathway (Stober et al., 2002).
517 Engagement of TLR signaling during cross-presentation is required for translocation of MHC-I to
518 cargo-containing phagosomes, where vacuolar cross-presentation can occur (Nair-Gupta et al.,
519 2014). Whether RUBCN plays a role in virus-initiated cross-presentation or the vacuolar pathway
520 of cross-presentation remains to be determined.
521
522 Increased cross-presentation can also be a contributing factor to the age-related autoimmunity
523 and inflammation observed in *Rubcn*$^{-/-}$ mice (Martinez et al., 2016b). Studies have linked cross-
524 presentation to increased autoimmunity. NOD mice, which are susceptible to the development of
525 diabetes mellitus, fail to develop invasive intra-islet insulitis or become diabetic in the absence of
526 MHC-I (Marino et al., 2012; Serreze et al., 1997). Compared to wild type mice, however, aged
527 *Rubcn*$^{-/-}$ mice exhibit increased levels of activated CD44^{+} CD62L^{-} CD8^{+} T cells in the periphery,
528 suggesting that increased MHC-I-mediated T cell activation is present in the absence of LAP
529 (Martinez et al., 2016b). It is possible that *Rubcn* deficiency bestows improved cross-presentation
530 capacity in other phagocytes, including macrophages, which have been described as poor cross-
531 presenters (Savina and Amigorena, 2007). Thus, tissue or cell type-specific *Rubcn*-deficient
532 animals may exhibit moderate or organ-restricted autoimmune pathology.
533
534 Similar to studies utilizing myeloid cell-specific deletion of *Rubcn* (Cunha et al., 2018), mice with
535 *Rubcn*-deficient DCs demonstrate a significant decrease in tumor burden in a xenograft model of

tumorigenesis, due to significantly increased cross-presentation capacity and an enhanced tumor antigen-specific $CD8^+$ T cell response. As cross-presentation by DCs is required for the effectiveness of anti-PD-1 and anti-CD137 immunotherapies in the B16 tumor model (Sanchez-Paulete et al., 2016), a combination of RUBCN inhibition and immune checkpoint inhibitors, such anti-PD-1 and anti-CTLA-4, may synergize for a more potent anti-tumor $CD8^+$ T cell response. If modulation of RUBCN activity affects the expression of PD-L1 or other inhibitory molecules on APCs remains an open avenue to explore.

Due to their diversity, plasticity, and efficient cross-presentation capacity, DCs can be exploited as vaccines to yield improved therapeutics (Saxena and Bhardwaj, 2018). Indeed, DC vaccines, such as Sipuleucel-T, have demonstrated remarkable efficacy in the treatment of prostate cancer via the capacity of autologous DCs to mount an effective and tumor-antigen-specific $CD8^+$ T cell response (Kantoff et al., 2010). Downregulation of *Rubcn* expression or activity in DCs *ex vivo* could provide additional benefit and further boost their efficacy *in vivo*. Collectively, our study demonstrates that LAP promotes an immunotolerant response by limiting cross-presentation, potentially as a mechanism to suppress excessive activation of $CD8^+$ T cells.

Acknowledgments

The authors thank the animal husbandry staff at NIEHS, as well as Carl Bortner, Maria Sifre, and Kevin S. Katen of the Flow Cytometry Core (NIEHS). We would also like to thank Seddon Y. Thomas, Hideki Nakano, Thomas H. Oguin, III, Donald N. Cook, and Michael Fessler for thoughtful insights and discussions. This work was supported by the NIH Intramural Research Program 1ZIAES10328601 to J.M.

Author Contributions

The project was conceived by P.S. and J.M. Mouse experiments were conducted by P.S., F.Z., J.P.K., and S.W.W. G.M., L.D., C.J.T., and E.S. provided technical assistance. S.G. provided bioinformatics support. A.S. and A.O. provided reagents and technical expertise. Writing and editing by P.S., J.P.K., G.M., and J.M.

Declarations of Interests

The authors declare no conflict of interest.

Figure Legends

Figure 1: *Rubcn*$^{-/-}$ DCs display enhanced cross-presentation capacity. Bone marrow-derived dendritic cells (DCs) were generated from *Rubcn*$^{+/+}$ (black) and *Rubcn*$^{-/-}$ (red) mice *in vitro* with FLT3-L for 7 days. (**A-B, D**) DCs were co-cultured with apoptotic B16-OVA cells (1 or 5 apoptotic cells: 1 DC). Eighteen hours later, DCs were harvested for flow cytometry analysis of H2-K^{b}-OVA$_{257-264}$ (**A**), H2-K^{b} (**B**), and CD86 (**D**) expression. (**C**) DCs were co-cultured with apoptotic Jurkat cells (5 apoptotic cells: 1 DC). Thirty minutes later, RNA was harvested for RNA-seq. Genes with fold change (FC>1.25) compared to no stimulation and $p<0.05$ (ANOVA) were considered significant and entered in DAVID and R studio for further pathway analysis. Heatmap of differentially regulated antigen presentation, activation, and cytokine/chemokine machinery depicted as row z-score is shown (n=3 per genotype). (**E-H**) DCs were co-cultured with apoptotic B16-OVA cells (1 or 5 apoptotic cells: 1 DC). Eighteen hours later, loaded DCs were co-cultured with naïve OT-I CD8^{+} T cells, labeled with Tag-it Proliferation dye. Forty-eight hours later, *in vitro* cultures were harvested for flow cytometry analysis of OT-I proliferation (**E, G-H**) or IFNγ production (**F**). Prior to OT-I addition, DCs were incubated with anti-IgG, anti-CD86, and/or conditioned media from independent cultures for at least 1 hour (**G-H**), as indicated. Data are expressed as mean ± SEM. No less than three independent experiments were performed, with

3-5 replicates per condition. Significance was calculated using 2-way ANOVA (*p<0.05, **p<0.01, ***p<0.001).

Figure 2: *Rubcn*$^{-/-}$ DCs engulf cargo, yet retain cargo in less degradative phagosomes. Bone marrow-derived dendritic cells (DCs) were generated from *Rubcn*$^{+/+}$ (black) and *Rubcn*$^{-/-}$ (red) mice *in vitro* with FLT3-L for 7 days. (**A-B**) GFP-LC3$^{+/+}$DCs were co-cultured with PKH26-labeled apoptotic B16-OVA cells (5 apoptotic cells: 1 DC). After one hour, phagocytosis of PKH26-labeled apoptotic B16-OVA cells was analyzed by flow cytometry (**A**). After four hours, DCs were harvested, permeabilized by digitonin (20 µg/ml), and GFP-LC3 fluorescence associated with PKH26^{+} events was analyzed by flow cytometry (**B**). (**C**) DCs were co-cultured with OVA-coated latex beads (5 beads: 1 DC) in chamber slides. Four hours later, DCs were fixed, permeabilized, stained for RAB5A (green) and LAMP2 (red), and imaged via confocal microscopy. Representative images are shown. (**D**) Apoptotic B16-OVA cells were labeled with pHrodo Red per manufacturer's instructions, then co-cultured with *Rubcn*$^{+/+}$ and *Rubcn*$^{-/-}$ DCs *in vitro*. Four hours later, pHrodo Red fluorescence was measured in DCs by flow cytometry, as a readout of phagosomal maturation. (**E**) DCs were co-cultured with OVA-coated latex beads (5 beads: 1 DC) in chamber slides. Four hours later, DCs were fixed, permeabilized, stained for Sec22b (blue), H2-Kb (red), and Calreticulin (green), and imaged via confocal microscopy. Representative images are shown. (**F**) Signal intensity profile for Sec22b across phagocytosed beads was quantified by Fiji. Data (intensity measurements across beads) are presented as mean ± SEM (n = 10-15 cells per genotype). Flow cytometric data are expressed as mean ± SEM. No less than three independent experiments were performed, with 3-5 replicates per condition. Significance was calculated using 2-way ANOVA (*p<0.05, **p<0.01, ***p<0.001).

Figure 3: *Rubcn*$^{-/-}$ DCs exhibit increased phagosome-to-cytosol escape and proteasome-mediated generation of peptides. Bone marrow-derived dendritic cells (DCs) were generated

612 from *Rubcn*$^{+/+}$ (black) and *Rubcn*$^{-/-}$ (red) mice *in vitro* with FLT3-L for 7 days. (**A-B**) DCs were
613 loaded with 1 μm CCF4, then co-cultured with apoptotic B16-OVA in the absence or presence of
614 β-lactamase (2 mg/ml) for 90 or 180 minutes at 4°C or 37°C. Uncleaved CCF4 was measured by
615 flow cytometry at an emission of 535 nm, and cleaved CCF4 was measured at an emission of
616 450 nm. Ratios of 450 nm : 535 nm was calculated by dividing the 450 nm MFI by the 535 nm
617 MFI from a single sample. (**C**) DCs were pre-treated with vehicle or chloroquine (CQ) at 1 or 10
618 μM for 2 hours and then co-cultured with apoptotic B16-OVA cells (5 apoptotic cells: 1 DC).
619 Eighteen hours later, DCs were harvested for flow cytometry analysis of H2-K^{b}-OVA$_{257-264}$
620 expression. (**D**) DCs were pre-treated with vehicle or MG-132 at 1 or 10 μM for 2 hours and then
621 co-cultured in fresh media with apoptotic B16-OVA cells (5 apoptotic cells: 1 DC). Eighteen hours
622 later, DCs were harvested for flow cytometry analysis of H2-K^{b}-OVA$_{257-264}$ expression. (**E**) DCs
623 were pre-treated with vehicle or Brefeldin A at 3 μg/ml for 2 hours and then co-cultured in fresh
624 media with apoptotic B16-OVA cells (5 apoptotic cells: 1 DC). Eighteen hours later, DCs were
625 harvested for flow cytometry analysis of H2-K^{b}-OVA$_{257-264}$ expression. Data are expressed as
626 mean ± SEM. No less than two independent experiments were performed, with 3-5 replicates per
627 condition. Significance was calculated using 2-way ANOVA (*p<0.05, **p<0.01, ***p<0.001).
628
629 **Figure 4: *Cd11-Cre Rubcn*$^{flox/flox}$ mice display decreased tumor burden and increased**
630 **antigen-specific CD8^{+} T cell activation.** 1 x 10^{6} B16-OVA cells were injected intradermally into
631 *Rubcn*$^{flox/flox}$ (black, n=5) or *Cd11-Cre*$^{+}$ *Rubcn*$^{flox/flox}$ (red, n=5) mice. (**A-B**) Tumor measurements
632 were recorded every 2-4 days. Significance for **A** was calculated using Mantel-Cox Test, and
633 significance for **B** was calculated using 2-way ANOVA (*p<0.05, **p<0.01, ***p<0.001). (**C-E**) On
634 day 16 post-injection, tumors were harvested for flow cytometry analysis. Tumors were assessed
635 for tumor cell death (Zombie-UV^{+} CD45^{neg}, **C**) and immune cell infiltration (CD45^{+}, **D**). (**E-F**)
636 Representative flow plots for CD11c^{+} CD103^{+} CD8α^{+} DCs. Percentage of and number of CD11c^{+}

637 $CD103^+$ $CD8\alpha^+$ DCs within $CD45^+$ population (**E**); MFI of H2-K^b-$OVA_{257-264}$ expression (**D**) are
638 expressed as mean ± SEM. (**G**) On day 16 post-injection, dLNs were harvested for flow cytometry
639 analysis. Percentage of $CD11c^+$ $CD103^+$ $CD8\alpha^+$ DCs and MFI of H2-K^b-$OVA_{257-264}$ expression are
640 expressed as mean ± SEM. (**H-I**) On day 16 post-injection, tumors were harvested for flow
641 cytometry analysis. Representative flow plots for $CD8\alpha^+$ $Tetramer^+$ T cells are shown in **G**.
642 Percentage of and number of $CD8\alpha^+$ $Tetramer^+$ T cells within $CD45^+$ population (**H**) and
643 percentage of $CD69^+$, $IFN\gamma^+$, $TNF\alpha^+$, and $Perforin^+$ CD8+ T cells within tumor (**I**) are expressed
644 as mean ± SEM. (**J**) On day 16 post-injection, dLNs were harvested for flow cytometry analysis.
645 Percentage of $CD8\alpha^+$ $Tetramer^+$ T cells and percentage of $CD69^+$ CD8+ T cells are expressed as
646 mean ± SEM. No less than three independent experiments were performed, with 5 replicates per
647 genotype. Significance was calculated using 2-way ANOVA (*p<0.05, **p<0.01, ***p<0.001).

648
649 **STAR Methods**

650
651 **Lead Contact and Materials Availability**

652 Reagents and mice used in this study will be made available under a standard material transfer
653 agreement. Requests for resources and reagents should be directed to and will be fulfilled by the
654 Lead Contact, Jennifer Martinez (jennifer.martinez3@nih.gov).

655
656 **Experimental Model and Subject Details**

657 **Mice**

658 **Strains.** Age (8-12 weeks), gender, and weight-matched littermates were used as wild type
659 controls. Mice were housed and bred in a specific-pathogen-free animal facility at the
660 NIEHS/NIH, under the guidance of the NIEHS Animal Care and Use Committee (ACUC) in
661 accordance with the Guide for the Care and Use of Animals.

662

663 *Rubcn*$^{-/-}$ mice have been previously described (Martinez et al., 2015). Conditional null ("Flox")
664 Rubicon mice were made from embryonic stem cells purchased from the European Conditional
665 Mouse Mutagenesis Program (EUCOMM Project 76467). *Rubcn*$^{flox/flox}$ transgenic mouse strains
666 were generated at the NIEHS animal facility and bred to *B6.Cg-Tg(Itgax-cre)1-1Reiz/J* (*CD11c-*
667 *Cre*$^{+}$ B6, Jax stock no. 008068) mice to generate *CD11c-Cre*$^{+}$ *Rubcn*$^{flox/flox}$.
668
669 *Ulk1*$^{-/-}$ mice were provided by M. Kundu (St. Jude Children's Research Hospital, Memphis,
670 TN, USA) (Kundu et al., 2008). *Atg7*$^{flox/flox}$ mice were obtained from M. Komatsu (Tokyo
671 Metropolitan Institute of Medical Science, Tokyo, Japan) (Komatsu et al., 2005) and bred to
672 *CD11c-Cre*$^{+}$ mice to generate *CD11c-Cre*$^{+}$ *Atg7*$^{flox/flox}$. *C57BL/6-Tg(TcraTcrb)1100Mjb/J* (OT-1
673 B6, Jax stock no. 003831) mice were purchased from Jackson Laboratories (Bar Harbor, ME,
674 USA) and were used as a source for OVA-specific CD8^{+} T cells (described below). All mouse
675 strains were maintained on a C57BL/6 background.
676
677 **Xenograft tumor model.** 1x10^{6} B16-OVA cells in endotoxin-free PBS (Thermo Fisher Scientific,
678 Waltham, Massachusetts, USA) were injected intradermally into the shaved back of the female
679 mice. The mice were monitored for tumor growth, and the tumors were measured using digital
680 calipers (Mitutoyo Corporation, Kanagawa, Japan). The tumor volume was determined using the
681 formula, $volume = short\ axis^2 \times long\ axis \times 0.523$ (in mm^3). The solid tumors and draining lymph
682 nodes (dLNs) were harvested in complete media (DMEM+ 10% FCS+ 1% Penicillin-streptomycin)
683 in a non-treated 6-well plate (Thermo Fisher Scientific, Waltham, Massachusetts, USA). The
684 tumor mass was mechanically dissociated using a sharp blade, and they were then enzymatically
685 dissociated by incubating in DMEM containing 50% Accutase (Life Technologies Corporation,
686 Waltham, Massachusetts, USA), 1% penicillin-streptomycin and 5% collagenase/ hyaluronidase
687 (STEMCELL Technologies Inc., Vancouver, British Columbia, Canada) for 1 hour at 37 ºC. The
688 tumor cells were filtered using 70 µm filters and washed with PBS. The single cell suspension

689 was prepared by resuspended the cells in MACs buffer (PBS with 0.5% BSA and 2mM EDTA).
690 The cells were then finally resuspended in 80% Percoll (GE Healthcare Bio-Sciences, Pittsburgh,
691 PA, USA) and carefully layered the 40% Percoll. Once the Percoll gradient was prepared, the
692 cells were centrifuged at 1200 x g with no brakes at 4 ºC. Finally, tumor-infiltrating immune cells
693 were collected at the interphase of 80%-40% Percoll gradient. The cells were washed twice with
694 endotoxin-free PBS (400 x g, 5 mins, 4 ºC) and finally resuspended in MACs buffer. The dLNs
695 were mashed in complete media, filtered using 70 µm filters, and washed twice with endotoxin-
696 free PBS. The single cell suspension was prepared by resuspended the cells in FACs buffer.
697 Tumor-infiltrating immune cells and dLN cells were used to perform subsequent analysis. All
698 injected cells were subjected to and passed the NIEHS Quality Assurance Laboratory (QAL)
699 testing prior to injection.
700
701 **Cell culture**
702 **Bone marrow-derived dendritic cells (DC) differentiation.** Bone marrow was extracted from
703 the 8-12-week-old male mice. The hind legs were removed and placed in cold complete media.
704 The muscle and connective tissues associated with the femur and tibia were removed. The bones
705 were then flushed with cold RPMI complete media (supplemented with 10% FCS (Hyclone, GE
706 Healthcare Bio-Sciences, Pittsburgh, PA, USA), 1% HEPES (Sigma-Aldrich Corporation, St.
707 Louis, Missouri, United States), 1% Glutamax (Life Technologies Corporation, Waltham,
708 Massachusetts, USA), 1% penicillin-streptomycin (Life Technologies Corporation, Waltham,
709 Massachusetts, USA) and 50 µM tissue culture-grade β-mercaptoethanol (β-ME) (Life
710 Technologies Corporation, Waltham, Massachusetts, USA) until they turned white. The BM cells
711 were then passed through a 70 µm cell strainer. The cells were then centrifuged and treated with
712 9 ml of ammonium chloride solution (STEMCELL Technologies Inc., Vancouver, British Columbia,
713 Canada) for 10 minutes on ice to lyse the red blood cells (RBCs). The cells were centrifuged twice
714 with endotoxin-free PBS (400 x g, 5 mins, 4 ºC) and counted. Freshly isolated BM cells were

715 cultured in complete medium supplemented with 200 ng/mL of recombinant FMS-like tyrosine
716 kinase-3 ligand (rFlt3L) (NIEHS Protein Expression Core Facility) at the density of 2 x 10^6 viable
717 cells per ml in Nunc™ non-treated flasks (Thermo Fisher Scientific, Waltham, Massachusetts,
718 USA) at 37 ºC. The media was exchanged every 2-3 days for fresh complete media with 200
719 ng/ml rFlt3L.
720
721 On day 6-8, Flt3L-derived DCs were harvested by collecting the non-adherent DCs in a centrifuge
722 tube. The adherent DCs were treated with 2mM EDTA (Invitrogen, Carlsbad, CA, USA) for 5 mins
723 to harvest them and were then collected in a centrifuge tube. The DCs were washed with
724 endotoxin-free PBS twice and plated for subsequent *in vitro* experiments. Purity was assessed
725 by FACS analysis, and cultures over 75% $CD11c^+$ $CD103^+$ $CD8\alpha^+$ were used for *in vitro*
726 experiments.
727
728 **DC co-culture.** DCs were played at 1 x 10^6/ml in triplicate in 96 well round bottom plates for *in*
729 *vitro* experiments. Apoptotic cells (below) were used at a ratio of 1 apoptotic cell : 1 DC or 5
730 apoptotic cells : 1 DC. Low endotoxin whole soluble OVA (sOVA) protein (Worthington
731 Biochemical, Lakewood, NJ USA) was used at 150 μg/ml. Alexa Fluor 555-conjugated OVA was
732 obtained from Thermo-Fisher Scientific (Waltham, MA, USA) and used at 150 μg/ml. $OVA_{257-264}$
733 peptide (Invivogen, San Diego, CA, USA) was used at 50 ng/ml. OVA (150 μg/ml) was coupled
734 to 3-micron polystyrene beads (Polysciences Inc., Warrington, PA USA) per manufacturer's
735 instructions. Chloroquine (CQ) was used at 1 or 10 μM to inhibit lysosomal fusion (Sigma-Aldrich,
736 St. Louis, MO USA). MG-132 was used at 1 or 10 μM to inhibit proteasome activity (Sigma-
737 Aldrich, St. Louis, MO USA). Brefeldin A was used at 3 μg/ml to inhibit protein transport (Thermo-
738 Fisher Scientific, Waltham, MA, USA).
739

740 **Cell lines.** B16-OVA cells were obtained from A. Oberst at the University of Washington, Seattle,
741 WA USA. The cells were cultured with complete DMEM media supplemented with 10% heat-
742 inactivated fetal bovine serum (HI-FCS) (Hyclone, GE Healthcare Bio-Sciences, Pittsburgh, PA,
743 USA), 1% penicillin-streptomycin (Penicillin-streptomycin) (Life Technologies Corporation,
744 Waltham, Massachusetts, USA) and 500 µg/ml geneticin (Life Technologies Corporation,
745 Waltham, Massachusetts, USA). The media was changed every 2 days. The cells were harvested
746 by trypsinization and washed twice with endotoxin-free PBS before use. The cells were confirmed
747 as negative for mycoplasma contamination by the NIEHS Quality Assurance Laboratory (QAL).
748 Jurkat cells were obtained from M. Fessler at the NIEHS, RTP, NC USA and cultured with
749 complete RPMI media supplemented with 10% heat-inactivated fetal bovine serum (HI-FCS)
750 (Hyclone, GE Healthcare Bio-Sciences, Pittsburgh, PA, USA) and 1% Penicillin-streptomycin (Life
751 Technologies Corporation, Waltham, Massachusetts, USA). The media was exchanged every 2-
752 3 days for fresh complete media. The cells were harvested by collecting all the non-adherent
753 cells, centrifuging, and washing with endotoxin-free PBS. The cells were confirmed as negative
754 for mycoplasma contamination by the NIEHS Quality Assurance Laboratory (QAL).
755
756 **Induction of Apoptosis in B16-OVA cells and Jurkat cells.** The cells were washed with
757 endotoxin-free PBS 2x to remove the media and then UV treated for 20 seconds with 20 J/m^2 in
758 a UV crosslinker (Fisher Scientific, Hampton, NH, USA) (Martinez et al., 2011b). The cells were
759 then returned to the 37 ºC incubator. 16 hours of post-UV treatment, the apoptotic cells were
760 detected by Annexin V and PI staining and performing FACs analysis (Martinez et al., 2016a, b).
761
762 **Naïve CD8$^+$ T cells isolation.** The spleens from naïve OT1 mice C57BL/6-
763 Tg(TcraTcrb)1100Mjb/J (OT-1 B6, Jax Stock No. 003831 Jackson Laboratories Bar Harbor, ME,
764 USA) were harvested and the CD8$^+$ T cells were extracted using EasySep™ Mouse Pan-Naïve
765 T Cell Isolation Kit per manufacturer's instructions. (STEMCELL Technologies Inc., Vancouver,

British Columbia, Canada). Isolated T cells were incubated in serum-free media for 2 hours to synchronize their cell cycles. Cells were then stained with Tag it ™ dye (Biolegend, San Diego, CA, USA) per manufacturer's instructions.

T cell : DC co-culture. $CD11c^+$ DCs were isolated from day 7 bone marrow-dervied DCs (above) using EasySep™ manufacturer's guidelines from the Mouse Pan-DC Enrichment Kit (STEMCELL Technologies Inc., Vancouver, British Columbia, Canada). 1x 10^5 $CD11c^+$ DCs were then co-cultured with apoptotic B16-OVA cells (1 or 5 apoptotic cells : 1 DC), sOVA protein (150 µg/ml), or $OVA_{257-264}$ peptide (50 ng/ml) in triplicate for 18 hours in a 96 well plate. Unstimulated or loaded $CD11c^+$ DCs were co-cultured with naïve isolated 1x 10^6 cell cycle-synchronized, Tag it ™-labeled $CD8^+$ OT-I T cells (above) for 2 days (10 T cells : 1 DC). T cell proliferation and production of IFNγ was measured by FACs after 48 hours of co-culture.

CD86 inhibition *in vitro*. T cell : DC co-culture was performed as described above with the following modifications. Prior to addition of OT-I T cells, antigen-loaded DCs were incubated with IgG2a isotype control antibody or anti-CD86 blocking antibody (Biolegend, San Diego, CA, USA) at 1 or 10 µg/ml for at least 1 hour. DCs were then co-cultured with naïve isolated 1x 10^6 cell cycle-synchronized, Tag it ™-labeled $CD8^+$ OT-I T cells (above) for 2 days (10 T cells : 1 DC). T cell proliferation was measured by FACs after 48 hours of co-culture.

Conditioned media. T cell : DC co-culture was performed as described above with the following modifications. Prior to addition of OT-I T cells, media was removed from antigen-loaded DCs, and DCs were gently washed with PBS. Culture media was collected from independent cultures of *Rubcn*$^{+/+}$ and *Rubcn*$^{-/-}$ DCs after 18 hours of culture with apoptotic B16-OVA cells. Conditioned media from *Rubcn*$^{-/-}$ DCs (KO conditioned media) was transferred to *Rubcn*$^{+/+}$ DCs, and conditioned media from *Rubcn*$^{+/+}$ DCs (WT conditioned media) was transferred to *Rubcn*$^{-/-}$ DCs.

Cultures were incubated for at least 1 hour with conditioned media, prior to addition of OT-I T cells. DCs were then co-cultured with naïve isolated 1x 10^6 cell cycle-synchronized, Tag it ^{TM}-labeled $CD8^+$ OT-I T cells (above) for 2 days (10 T cells : 1 DC). T cell proliferation was measured by FACs after 48 hours of co-culture.

Method Details

Quantification of phagocytosis. Phagocytosis was calculated using flow cytometry analysis as described in (Martinez et al., 2015). The percentage of phagocytosis equals the number of dendritic cells that have been engulfed PKH26-stained B16-OVA. Data represent a minimum of three independent experiments in which technical triplicates of 50,000 cells per sample were acquired using a Fortessa cytometer (BD, Franklin Lake, NJ, USA).

Quantification of GFP-LC3 translocation to the phagosome. GFP-LC3 association with the cargo-containing phagosome was assessed by flow cytometry using methods previously described (Martinez et al., 2015) (Shvets and Elazar, 2009)**.** Briefly, apoptotic B16-OVA cells were labeled with PKH26and co-cultured with *Rubcn*$^{+/+}$ and *Rubcn*$^{-/-}$ DCs that express the transgene for GFP-LC3. After four hours, GFP-$LC3^+$ DCs were harvested, washed once with FACS buffer, and permeabilized on ice with digitonin (20 µg/ml) for 15 minutes. GFP-LC3 association with $PKH26^+$ apoptotic cell-containing phagosomes was measured by examining mean fluorescent intensity (MFI) of GFP-LC3 of $PKH26^+$ events (Shvets and Elazar, 2009). Data represent a minimum of three independent experiments in which technical triplicates of 50,000 cells per sample were acquired using a Fortessa cytometer (BD, Franklin Lakes, New Jersey, USA).

pHrodo labeling. Low endotoxin OVA protein was labeled with pHrodo Red Microscale Labeling Kit (Thermo-Fisher Scientific, Waltham, Massachusetts, USA) per manufacturer's instructions.

B16-OVA cells were labeled with pHrodo Red AM Intracellular pH Indicator kit (Thermo-Fisher Scientific, Waltham, Massachusetts, USA) per manufacturer's instructions.

Cell labeling with PKH26 dye. The apoptotic cells were stained using the PKH26 Red Fluorescent Cell Linker Kits (Sigma-Aldrich, St. Louis, Missouri, USA) per manufacturer's protocol (Martinez et al., 2016a, b). The cell pellet was resuspended in 10 ml of complete medium, transfer to a fresh sterile conical polypropylene tube, centrifuge at 400 x g for 5 minutes and washed the cell pellet 2 more times with 10 ml of complete medium to ensure removal of unbound dye.

Digitonin-based measurement phagosome-to-cytosol escape assay. Phagosomal escape using a modified version of a previously described protocol (Repnik et al., 2016). Briefly, cells were cultured with PKH26-labeled apoptotic B16-OVA cells (5 apoptotic cells: 1 DC) or Alexa Fluor 555-labeled OVA protein (150 µg/ml). Six hours later, DCs were permeabilized with digitonin (20 µg/ml) incubating the plate for 10 minutes on ice with shaking. Membrane portions of the sample were pelleted by centrifugation (14,000 rpm, 1 hour). Cytosolic supernatant portions were collected and analyzed for fluorescence as indicated using Tecan M200 Infiniti Pro microplate reader (Tecan, Männedorf, Switzerland).

For measurement of cytosolic cathepsin, DCs were permeabilized with 20 µg/ml or 200 µg/ml for 10 minutes on ice with shaking. DCs then treated with 5 mM DTT and 30 µM cathepsin-specific fluorogenic substrate, Z-FR-AMC (Sigma-Aldrich, St. Louis, MO USA) at 37°C for 20 minutes. Membrane portions of the sample were pelleted by centrifugation (14,000 rpm, 1 hour). Cytosolic supernatant portions were collected and analyzed for AMC (ex 370 nm; em 460 nm) fluorescence using Tecan M200 Infiniti Pro microplate reader.

β-lactamase-based measurement of phagosome-to-cytosol escape assay. Phagosomal escape using a modified version of a previously described protocol (Cebrian et al., 2011; Keller et al., 2013). DCs were loaded with 1 μM FRET substrate, CCF4 (Thermo-Fisher Scientific, Waltham, Massachusetts, US), which accumulates in the cytosol and emits a FRET signal at 535 nm when it is uncleaved for 1 hour at room temperature in EM buffer (120mM NaCl, 7mM KCl, 1.8mM CaCl2, 0.8mM MgCl2, 5mM glucose and 25mM HEPES at pH 7.3). Cells were washed once and co-culture apoptotic B16-OVA cells (5 apoptotic cells : 1 DC) in the absence or presence of 2 mg/ml of purified β-lactamase (Sigma-Aldrich, St. Louis, MO USA) in EM buffer with 1mM probenecid (Sigma-Aldrich, St. Louis, MO USA) for 90 or 180 minutes at 4°C or 37°C. Using flow cytometry, live, single cells were gated, and the mean fluorescent intensities of CCF4 fluorescence with 450nm and 535nm emission filters was measured. Ratiometric values of both signals (450 nm : 535 nm, as a ratio of cleaved CCF4 to uncleaved CCF4) was calculated as a means of examining β-lactamase export to the cytosol (Loi et al., 2016).

qPCR. *Rubcn*$^{+/+}$ and *Rubcn*$^{-/-}$ FLT3L-derived-BMDCs were unstimulated or co-cultured with apoptotic Jurkat cells (5 apoptotic cells : 1 DC). RNA was isolated after thirty minutes using the Trizol and RNeasy kit (QIAGEN, Hilden, Germany) according to the manufacturer's instructions. The RNA was treated with DNase (QIAGEN, Hilden, Germany) to ensure the removal of any contaminating DNA. Extracted RNA was reverse transcribed to cDNA using iScript cDNA synthesis kit (Bio-Rad Laboratories, Hercules, California, U.S.A.). Quantitative, real-time PCR was performed on the QuantStudio 6 Flex Real-Time PCR System (Applied Biosystems, Thermo-Fisher Scientific, Waltham, MA, USA) using TaqMan Universal Master Mix (Applied Biosystems, Waltham, Massachusetts, USA). *Rubcn* (Mm01170688_g1), *Tap 1* (Mm00443188_m1), *Tap 2* (Mm01277033_m1), *β2m* (Mm00437762_m1), and *Actinb* (Mm02619580_g1) TaqMan assay (Life Technologies, Thermo-Fisher Scientific, Waltham, MA, USA) were used. Expression was normalized against *Actinb* to compare target gene mRNA levels.

869

870 **RNA-seq.** *Rubcn*$^{+/+}$ and *Rubcn*$^{-/-}$ FLT3L-derived-BMDCs were unstimulated or co-cultured with
871 apoptotic Jurkat cells (5 apoptotic cells: 1 DC). RNA was isolated after thirty minutes using the
872 Trizol and RNeasy kit (QIAGEN, Hilden, Germany) according to the manufacturer's instructions.
873 DNase digestion was performed to remove genomic DNA as described above. The sample
874 concentration was measured using the Qubit RNA BR Assay kit (Invitrogen, Carlsbad, CA, USA)
875 and the RNA quality was rechecked with Bioanalyzer 2100 (Agilent, Santa Clara, CA, USA) with
876 RNA Pico chip (Agilent, Santa Clara, CA, USA). 250 ng of RNA was used to make RNA-seq
877 library using Illumina's TruSeq RNA Library Prep Kit v2. The library concentration was checked
878 using Qubit dsDNA HS assay kit (Invitrogen, Carlsbad, CA, USA) and the library's fragment size
879 range with Bioanalyzer 2100 using high sensitivity DNA Chip (Agilent, Santa Clara, CA, USA).
880 Then the library was then prepped for sequencing. Sequencing was performed with an Illumina
881 NovaSeq 6000 (Illumina, San Diego, CA, USA) by the NIEHS Epigenomics Core.

882

883 Reads were generated as single-end 76mers then filtered to retain only those with an average
884 base quality score of at least 20. Genomic mapping against the mm10 reference genome was
885 performed by STAR v2.5 (Dobin et al., 2013) with the following parameters: --
886 outMultimapperOrder Random --outSAMattrIHstart 0 --outfitter type BySJout --
887 alignSJoverhangMin 8 --limitBAMsortRAM 55000000000 (other parameters at default settings).
888 Mapped read counts per gene were determined by Subread feature Counts v1.5.0-p1 (Liao et al.,
889 2014) with parameter -s0. Differentially expressed genes (DEGs) were identified by DESeq2
890 v1.14.1 (Love et al., 2014) with filtering threshold FDR 0.05. Gene models for this analysis are
891 based on mm10 RefSeq annotations as downloaded from the UCSC Genome Browser.

892

893 The heatmap views for the dataset were generated by heatmap.2 from the gplots R package (R
894 studio, Boston, MA, USA), with row-scaling of the expression values reported by the

rlogTransformation function in DESeq2. Ingenuity Pathway Analysis software (Qiagen, Venlo, The Netherlands) was used for further RNA-seq data analysis. The RNA-seq data have been deposited in NCBI's GEO (https://www.ncbi.nlm.nih.gov/geo/) under accession GSE133945.

Western blot. BMDCs were harvested, and the pellets were washed twice with PBS (400 x g, 5 mins, 4 ºC). Cells were resuspended in 200 µl of RIPA buffer containing proteinase inhibitor and mixed thoroughly. The cells were lysed on ice for 30 minutes and vortexed for 10 seconds every 10 minutes. For analysis of *Cd11-Cre*-mediated deletion, spleens from *Rubcn*$^{flox/flox}$ or *Cd11-Cre*$^{+}$ *Rubcn*$^{flox/flox}$ mice were harvested, and CD11c^{+} populations were isolated using EasySep™ manufacturer's guidelines from the Mouse Pan-DC Enrichment Kit (STEMCELL Technologies Inc., Vancouver, British Columbia, Canada).

Cell lysates were mixed with 2x Loading buffer, and samples were loaded onto protein gel for separation by molecular weight. Proteins on the gel were transferred onto polyvinylidene difluoride (PVDF) membranes using a Trans-Blot semi-dry transfer cell (Bio-Rad, Hercules, CA USA). The membranes were blocked with Tris-buffered saline containing 0.05% Tween 20 (TBST) and 5% bovine serum albumin (BSA) for 1 hour and incubated with primary antibodies overnight at 4°C. Membranes were washed with PBS containing 0.05% Tween 20 (PBST) or TBST and incubated with horseradish peroxidase (HRP)-conjugated secondary antibodies (Jackson ImmunoResearch, West Grove, PA, USA) for 1 hour, and the HRP on the membranes was developed with ECL Select Western blotting detection reagent and visualized using an ImageQuant LAS 4000 (GE Healthcare, Pittsburgh, PA USA).

Flow cytometry. Cells were resuspended in FACs buffer and blocked using anti-mouse CD16/CD32 (Biolegend, San Diego, CA, USA). Zombie UV (Biolegend, San Diego, CA, USA) or Fixable Viability eFluor™ 780 (Thermo-Fisher Scientific, Waltham, MA, USA) dyes were used to

stain for cell viability. Cells were stained with FACs antibodies for surface markers, then washed with FACs buffer. 50,000 cells per sample were acquired using the LSRII or Fortessa flow cytometer (BD, Franklin Lakes, NJ, USA) and analyzed using FlowJo software (Tree Star, Ashland, OR, USA). Geometric mean fluorescence intensity (MFI) was calculated for markers of DC activation, such as CD86 and H2-K^b-$OVA_{257-264}$ (MHC-I SIINFEKL). Antigen-specific T cells were detected using H2-K^b-$OVA_{257-264}$ Tetramer (NIH Tetramer Core Facility, Atlanta, GA, USA), For Tetramer staining, the samples were incubated with the Tetramer prepared in MACs buffer for 1 hour at room temperature, washed and before additional surface stains.

FACs intracellular cytokine staining. For intracellular cytokine staining, cells were incubated with 500 ng/ml PMA (Sigma-Aldrich Corporation, St. Louis, Missouri, United States), 1 µg/ml Ionomycin (Sigma-Aldrich Corporation, St. Louis, Missouri, United States), and 3 µg/ml Brefeldin A (Thermo-Fisher Scientific, Waltham, MA, USA) for 6 hours at 37°C post-surface marker staining. Cells were fixed and permeabilized in BD Cytofix/Cytoperm™ (Becton Dickinson, Franklin Lakes, NJ, USA) per manufacturer's guidelines, and stained with intracellular antibodies (Perforin, IFNγ, TNFα).

Immunofluorescence. BMDCs were plated and stimulated in poly-D-Lysine (1 mg/ml)-coated chamber slides. At indicated time points, cells were fixed with 4% formaldehyde for 20 minutes at 4°C. Following fixation, cells were blocked and permeabilized in block buffer (1% BSA, 0.1% Triton in PBS) for 1 hour at RT. Cells were incubated overnight at 4°C with the primary antibody in block buffer. Cells were washed in TBS-Tween (Tris-buffered saline containing 0.05% Tween-20) and incubated Alexa-Fluor conjugated secondary antibodies (Thermo Fisher Scientific, Waltham, MA, USA). Confocal images were taken with a Zeiss LSM880 (Carl Zeiss Inc, Oberkochen, Germany) using the 488nm, 561nm, and 633nm laser lines for excitation paired with

emission filter setting of 495-558nm, 571-624nm, and 640-758nm respectively. An EC Plan-Neofluar 40X/0.9 M27 objective was used for image collection along with a pinhole setting of 3.4 Airy Units which yields an optical slice of 3.2um.

Quantification of immunofluorescence. ImageJ Fiji software (Schindelin et al., 2012) was used to quantitate the fluorescence intensity across the bead-containing phagosome. The images were imported into the Fiji software and a region of interest was selected to determine the mean fluorescent intensity. Data was compiled from 10-15 cells per treatment over three independent experiments.

Live cell imaging. 1 x10^6 DCs were seeded on 50 µg/ml poly-D-Lysine ((Sigma-Aldrich Corporation, St. Louis, Missouri, USA)-precoated 35 mm, Petri dish (MatTek Corporation, Ashland, MA). 5 x10^6 PKH26-labeled apoptotic B16-OVA cells were added to the culture. The cells were maintained at ~37 ◦C and 5% CO2 using an environmental control chamber. Confocal images were taken with a Zeiss LSM880 (Carl Zeiss Inc, Oberkochen, Germany) using the 561nm laser line for excitation paired with emission filter settings of 571-624nm. A Plan-APOCHROMAT 63X/1.4 Oil DIC objective was used for image collection along with a pinhole setting of 2.3 Airy units which yields an optical slice of 2 µm.

Quantification of cytokine and chemokine production. Supernatants from DC cultures were collected 18 hours after co-culture with apoptotic B16-OVA cells (5 apoptotic cells : 1 DC). The Bio-Plex® Multiplex Immunoassay System (Bio-Rad, Hercules, CA) was used following the manufacturer's instructions to detect the cytokines and chemokines released from the co-cultures. IFNβ was detected using Legend Max IFNβ ELISA kit (Biolegend, San Diego, CA, US). Data (mean ± SEM) represent three independent experiments from 5 mice per genotype.

Statistical Analysis. All data were statistically analyzed using GraphPad Prism software v6.01 (GraphPad Software, La Jolla, CA, USA). The statistical significance was determined by a Student t-test or two-way ANOVA with multiple comparison test (MCT) as indicated in the figure legends and $p < 0.05$ was considered significant.

Supplemental Information Legends

Figure S1, related to Figure 1: *Rubcn*$^{-/-}$ DCs display increased cross-presentation capacity but equivalent levels of peptide-mediated MHCI antigen presentation. Bone marrow-derived dendritic cells (DCs) were generated from *Rubcn*$^{+/+}$ (black) and *Rubcn*$^{-/-}$ (red) mice *in vitro* with FLT3-L for 7 days. (**A**) DCs were harvested for Western blot analysis of RUBCN and β-actin expression. (**B**) Representative flow cytometry plots for DCs on day 7 post-differentiation. (**C**) DCs were co-cultured with apoptotic B16-OVA cells (1 or 5 apoptotic cells: 1 DC) at 4°C. Eighteen hours later, DCs were harvested for flow cytometry analysis of H2-K^b and H2-K^b-OVA$_{257-264}$ expression. (**D**) DCs were co-cultured with apoptotic Jurkat cells (5 apoptotic cells: 1 DC). Six hours later, RNA was harvested for qPCR of cross-presentation machinery, *Tap1*, *Tap2*, *B2m*, and *Rubcn*. Data are normalized to *Actinb* expression and expressed as mean ± SEM. (**E**) DCs were co-cultured with apoptotic B16-OVA cells (5 apoptotic cells: 1 DC). Eighteen hours later, co-culture supernatant was collected and analyzed for cytokine and chemokine production by multiplex or ELISA technology. (**F**) DCs were co-cultured with OVA$_{257-264}$ peptide (50 ng/ml) or sOVA protein (150 μg/ml). Eighteen hours later, DCs were harvested for flow cytometry analysis of H2-K^b-OVA$_{257-264}$ expression. (**G-H**) DCs were co-cultured with OVA$_{257-264}$ peptide (50 ng/ml) or sOVA protein (150 μg/ml). Eighteen hours later, loaded DCs were co-cultured with naïve OT-I CD8$^+$ T cells, labeled with Tag-it Proliferation dye. Forty-eight hours later, *in vitro* cultures were harvested for flow cytometry analysis of OT-I proliferation (**G**) or IFNγ production (**H**). Data are expressed as mean ± SEM. No less than three independent experiments were performed, with

998 3-5 replicates per condition. Significance was calculated using 2-way ANOVA (*p<0.05, **p<0.01,
999 ***p<0.001).
1000
1001 **Figure S2, related to Figure 1: Defects in LAP, not canonical autophagy, results in**
1002 **increased cross-presentation.** (**A-B**) Bone marrow-derived dendritic cells (DCs) were
1003 generated from *Rubcn*$^{+/+}$ (black) and *Rubcn*$^{-/-}$ (red) mice *in vitro* with FLT3-L for 7 days. DCs were
1004 co-cultured with apoptotic B16-OVA cells (5 apoptotic cells: 1 DC). Eighteen hours later, loaded
1005 DCs incubated with anti-IgG, anti-CD86, and/or conditioned media from independent cultures, as
1006 indicated for at least 1 hour. DCs were then were co-cultured with naïve OT-I CD8^{+} T cells,
1007 labeled with Tag-it Proliferation dye. Forty-eight hours later, *in vitro* cultures were harvested for
1008 flow cytometry flow cytometry analysis of OT-I proliferation. Representative histograms are
1009 shown. (**C-D**). Bone marrow-derived dendritic cells (DCs) were generated from *Ulk1*$^{+/+}$ (black)
1010 and *Ulk1*$^{-/-}$ (blue) mice *in vitro* with FLT3-L for 7 days. DCs were co-cultured with sOVA protein
1011 (150 μg/ml) or apoptotic B16-OVA cells (5 apoptotic cells: 1 DC). Eighteen hours later, DCs were
1012 harvested for flow cytometry analysis of H2-K^{b}-OVA$_{257-264}$ expression (**C**). DCs were co-cultured
1013 sOVA protein (150 μg/ml) or apoptotic B16-OVA cells (5 apoptotic cells: 1 DC). Eighteen hours
1014 later, loaded DCs were co-cultured with naïve OT-I CD8^{+} T cells, labeled with Tag-it Proliferation
1015 dye. Forty-eight hours later, *in vitro* cultures were harvested for flow cytometry analysis of OT-I
1016 proliferation (**D**). (**E-F**). Bone marrow-derived dendritic cells (DCs) were generated from *Atg7*$^{flox/flox}$
1017 (black) and *Cd11c-Cre*$^{+}$ *Atg7*$^{flox/flox}$ (green) mice *in vitro* with FLT3-L for 7 days. DCs were co-
1018 cultured with sOVA protein (150 μg/ml) or apoptotic B16-OVA cells (5 apoptotic cells: 1 DC).
1019 Eighteen hours later, DCs were harvested for flow cytometry analysis of H2-K^{b}-OVA$_{257-264}$
1020 expression (**E**). DCs were co-cultured sOVA protein (150 μg/ml) or apoptotic B16-OVA cells (5
1021 apoptotic cells: 1 DC). Eighteen hours later, loaded DCs were co-cultured with naïve OT-I CD8^{+}
1022 T cells, labeled with Tag-it Proliferation dye. Forty-eight hours later, *in vitro* cultures were

harvested for flow cytometry analysis of OT-I proliferation (**F**). Data are expressed as mean ± SEM. No less than three independent experiments were performed, with 3-5 replicates per condition. Significance was calculated using 2-way ANOVA (*p<0.05, **p<0.01, ***p<0.001).

Figure S3, related to Figures 2 and 3: *Rubcn*$^{-/-}$ DCs display increased phagosome-to-cytosol escape and sensitive to proteasome inhibition. Bone marrow-derived dendritic cells (DCs) were generated from *Rubcn*$^{+/+}$ (black) and *Rubcn*$^{-/-}$ (red) mice *in vitro* with FLT3-L for 7 days. (**A**) DCs were co-cultured with apoptotic Jurkat cells (5 apoptotic cells: 1 DC). Thirty minutes later, RNA was harvested for RNA-seq. Genes with fold change (FC>1.25) compared to no stimulation and p<0.05 (ANOVA) were considered significant and entered in Ingenuity Pathway Analysis (IPA) and R studio for further pathway analysis. Heatmap of lysosomal machinery depicted as average row z-score is shown (n=3 per genotype). (**B**) DCs were co-cultured with PKH26-labeled apoptotic B16-OVA cells (5 apoptotic cells: 1 DC). Time-lapse imaging was performed for 6 hours to examine the rate of clearance of apoptotic cells. Mean fluorescence of PKH26 per field was obtained from images using Fiji. Data are expressed as mean ± SEM. (n=15 fields per timepoint per condition). (**C**) sOVA protein was labeled with pHrodo Red per manufacturer's instructions, then co-cultured (150 µg/ml) with *Rubcn*$^{+/+}$ and *Rubcn*$^{-/-}$ DCs *in vitro*. Four hours later, pHrodo Red fluorescence was measured in DCs by flow cytometry, as a readout of phagosomal maturation. (**D**) DCs were plated in in chamber slides, and were fixed, permeabilized, stained for Sec22b (blue), H2-K^{b} (red), and Calreticulin (green), and imaged via confocal microscopy. Co-localization of Sec22b and Calreticulin was obtained from images using Fiji. Data are expressed as mean ± SEM (n=15 cells per condition). (**E**) DCs were permeabilized with 20 µg/ml or 200 µg/ml digitonin, then incubated with cathepsin-specific fluorogenic substrate, Z-FR-AMC (30 µM), which emits fluorescence at 460 nm upon cathepsin-mediated cleavage. Membrane portions of samples were pelleted by centrifugation, and cytosolic supernatant portions were collected and analyzed for fluorescence (460 nm) using Tecan microplate reader. (**F-G**).

DCs were co-cultured with PKH26-labeled apoptotic B16-OVA cells (5 apoptotic cells: 1 DC, **F**) or Alexa Fluor 555-labeled sOVA protein (150 μg/ml, **G**). Six hours later, DCs were permeabilized with digitonin (20 μg/ml), and membrane portions of samples were pelleted by centrifugation. Cytosolic supernatant portions were collected and analyzed for fluorescence (567 nm [**F**] or 580 nm [**G**]) using Tecan microplate reader. (**H**) DCs were pre-treated with vehicle or chloroquine (CQ) at 1 or 10 μM for 2 hours and then co-cultured with sOVA protein (150 μg/ml). Eighteen hours later, DCs were harvested for flow cytometry analysis of H2-K^b-$OVA_{257-264}$ expression. (**I**) DCs were pre-treated with vehicle or MG-132 at 1 or 10 μM for 2 hours and then co-cultured in fresh media with sOVA protein (150 μg/ml). Eighteen hours later, DCs were harvested for flow cytometry analysis of H2-K^b-$OVA_{257-264}$ expression. (**J**) DCs were co-cultured with apoptotic Jurkat cells (5 apoptotic cells: 1 DC). Thirty minutes later, RNA was harvested for RNA-seq. Genes with fold change (FC>1.25) compared to no stimulation and $p<0.05$ (ANOVA) were considered significant and entered in Ingenuity Pathway Analysis (IPA) and R studio for further pathway analysis. Heatmap of proteasome machinery depicted as average row z-score is shown (n=3 per genotype). (**K**) DCs were pre-treated with vehicle or Brefeldin A at 3 μg/ml for 2 hours and then co-cultured in fresh media with sOVA protein (150 μg/ml). Eighteen hours later, DCs were harvested for flow cytometry analysis of H2-K^b-$OVA_{257-264}$ expression. Data are expressed as mean ± SEM. No less than two independent experiments were performed, with 3-5 replicates per condition. Significance was calculated using 2-way ANOVA (*$p<0.05$, **$p<0.01$, ***$p<0.001$).

Figure S4, related to Figure 4: *Cd11c-Cre Rubcn*$^{flox/flox}$ mice display increased anti-tumor immunity at day 22 *in vivo*. **(A)** Spleens from *Rubcn*$^{flox/flox}$ and *Cd11-Cre*$^+$ *Rubcn*$^{flox/flox}$ littermates were harvested. $CD11c^+$ cells were isolated via magnetic bead separation and subjected to Western blot analysis for RUBCN and β-actin expression. (**B**) 1 x 10^6 B16-OVA cells were injected intradermally into *Rubcn*$^{flox/flox}$ (black, n=7) or *Cd11-Cre*$^+$ *Rubcn*$^{flox/flox}$ (red, n=8) mice. Tumor growth for individual mice was monitored and recorded. (**C**) 1 x 10^6 B16-OVA cells were injected

intradermally into *Rubcn*$^{flox/flox}$ (black, n=5) or *Cd11-Cre*$^{+}$ *Rubcn*$^{flox/flox}$ (red, n=5) mice. On day 16 post-injection, tumors harvested for flow cytometry analysis. Representative flow cytometry plots and gating strategies for tumor-infiltrating immune cells are shown. **(D**) On day 16 post-injection, tumors were harvested for flow cytometry analysis. Percentage of F480^{+} macrophages (Mθs) within CD45^{+} population and MFI of H2-K^{b}-OVA$_{257-264}$ expression are expressed as mean ± SEM. (**E-F**) On day 22 post-injection, tumors were harvested for flow cytometry analysis.. Percentage of CD11c^{+} CD103^{+} CD8α^{+} DCs within CD45^{+} population and MFI of H2-K^{b}-OVA$_{257-264}$ expression (**E**) are expressed as mean ± SEM. Percentage of CD8α^{+} Tetramer^{+} T cells within CD45^{+} population and percentage of CD69^{+}, IFNγ^{+}, TNFα^{+}, and Perforin^{+} CD8+ T cells within tumor (**F**) are expressed as mean ± SEM. No less than three independent experiments were performed, with 5 replicates per genotype. Significance was calculated using 2-way ANOVA (*p<0.05, **p<0.01, ***p<0.001).

References

Alloatti, A., Rookhuizen, D.C., Joannas, L., Carpier, J.M., Iborra, S., Magalhaes, J.G., Yatim, N., Kozik, P., Sancho, D., Albert, M.L., and Amigorena, S. (2017). Critical role for Sec22b-dependent antigen cross-presentation in antitumor immunity. J Exp Med *214*, 2231-2241.

Andrieu, M., Desoutter, J.F., Loing, E., Gaston, J., Hanau, D., Guillet, J.G., and Hosmalin, A. (2003). Two human immunodeficiency virus vaccinal lipopeptides follow different cross-presentation pathways in human dendritic cells. J Virol *77*, 1564-1570.

Belizaire, R., and Unanue, E.R. (2009). Targeting proteins to distinct subcellular compartments reveals unique requirements for MHC class I and II presentation. Proc Natl Acad Sci U S A *106*, 17463-17468.

Blachere, N.E., Darnell, R.B., and Albert, M.L. (2005). Apoptotic cells deliver processed antigen to dendritic cells for cross-presentation. PLoS Biol *3*, e185.

Boya, P., Gonzalez-Polo, R.A., Poncet, D., Andreau, K., Vieira, H.L., Roumier, T., Perfettini, J.L., and Kroemer, G. (2003). Mitochondrial membrane permeabilization is a critical step of lysosome-initiated apoptosis induced by hydroxychloroquine. Oncogene *22*, 3927-3936.

Brasel, K., De Smedt, T., Smith, J.L., and Maliszewski, C.R. (2000). Generation of murine dendritic cells from flt3-ligand-supplemented bone marrow cultures. Blood *96*, 3029-3039.

Burgdorf, S., Lukacs-Kornek, V., and Kurts, C. (2006). The mannose receptor mediates uptake of soluble but not of cell-associated antigen for cross-presentation. J Immunol *176*, 6770-6776.

Burgdorf, S., Scholz, C., Kautz, A., Tampe, R., and Kurts, C. (2008). Spatial and mechanistic separation of cross-presentation and endogenous antigen presentation. Nat Immunol *9*, 558-566.

Calderon, B., and Unanue, E.R. (2012). Antigen presentation events in autoimmune diabetes. Curr Opin Immunol *24*, 119-128.

1111 Cebrian, I., Visentin, G., Blanchard, N., Jouve, M., Bobard, A., Moita, C., Enninga, J., Moita, L.F.,
1112 Amigorena, S., and Savina, A. (2011). Sec22b regulates phagosomal maturation and antigen
1113 crosspresentation by dendritic cells. Cell *147*, 1355-1368.
1114 Cruz, F.M., Colbert, J.D., Merino, E., Kriegsman, B.A., and Rock, K.L. (2017). The Biology and
1115 Underlying Mechanisms of Cross-Presentation of Exogenous Antigens on MHC-I Molecules.
1116 Annu Rev Immunol *35*, 149-176.
1117 Cunha, L.D., Yang, M., Carter, R., Guy, C., Harris, L., Crawford, J.C., Quarato, G., Boada-
1118 Romero, E., Kalkavan, H., Johnson, M.D.L.*, et al.* (2018). LC3-Associated Phagocytosis in
1119 Myeloid Cells Promotes Tumor Immune Tolerance. Cell *175*, 429-441 e416.
1120 Dobin, A., Davis, C.A., Schlesinger, F., Drenkow, J., Zaleski, C., Jha, S., Batut, P., Chaisson, M.,
1121 and Gingeras, T.R. (2013). STAR: ultrafast universal RNA-seq aligner. Bioinformatics *29*, 15-21.
1122 Fehres, C.M., Unger, W.W., Garcia-Vallejo, J.J., and van Kooyk, Y. (2014). Understanding the
1123 biology of antigen cross-presentation for the design of vaccines against cancer. Front Immunol *5*,
1124 149.
1125 Garcia-Mata, R., Szul, T., Alvarez, C., and Sztul, E. (2003). ADP-ribosylation factor/COPI-
1126 dependent events at the endoplasmic reticulum-Golgi interface are regulated by the guanine
1127 nucleotide exchange factor GBF1. Mol Biol Cell *14*, 2250-2261.
1128 Greenwald, R.J., Freeman, G.J., and Sharpe, A.H. (2005). The B7 family revisited. Annu Rev
1129 Immunol *23*, 515-548.
1130 Gutierrez-Martinez, E., Planes, R., Anselmi, G., Reynolds, M., Menezes, S., Adiko, A.C.,
1131 Saveanu, L., and Guermonprez, P. (2015). Cross-Presentation of Cell-Associated Antigens by
1132 MHC Class I in Dendritic Cell Subsets. Front Immunol *6*, 363.
1133 Hansen, T.H., and Bouvier, M. (2009). MHC class I antigen presentation: learning from viral
1134 evasion strategies. Nat Rev Immunol *9*, 503-513.
1135 Hayashi, K., Taura, M., and Iwasaki, A. (2018). The interaction between IKKalpha and LC3
1136 promotes type I interferon production through the TLR9-containing LAPosome. Sci Signal *11*.
1137 Heckmann, B.L., Teubner, B.J.W., Tummers, B., Boada-Romero, E., Harris, L., Yang, M., Guy,
1138 C.S., Zakharenko, S.S., and Green, D.R. (2019). LC3-Associated Endocytosis Facilitates beta-
1139 Amyloid Clearance and Mitigates Neurodegeneration in Murine Alzheimer's Disease. Cell *178*,
1140 536-551 e514.
1141 Henault, J., Martinez, J., Riggs, J.M., Tian, J., Mehta, P., Clarke, L., Sasai, M., Latz, E.,
1142 Brinkmann, M.M., Iwasaki, A.*, et al.* (2012). Noncanonical autophagy is required for type I
1143 interferon secretion in response to DNA-immune complexes. Immunity *37*, 986-997.
1144 Hogquist, K.A., Jameson, S.C., Heath, W.R., Howard, J.L., Bevan, M.J., and Carbone, F.R.
1145 (1994). T cell receptor antagonist peptides induce positive selection. Cell *76*, 17-27.
1146 Huang, A.Y., Golumbek, P., Ahmadzadeh, M., Jaffee, E., Pardoll, D., and Levitsky, H. (1994).
1147 Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens. Science
1148 *264*, 961-965.
1149 Jantas, D., Greda, A., Leskiewicz, M., Grygier, B., Pilc, A., and Lason, W. (2015). Neuroprotective
1150 effects of mGluR II and III activators against staurosporine- and doxorubicin-induced cellular injury
1151 in SH-SY5Y cells: New evidence for a mechanism involving inhibition of AIF translocation.
1152 Neurochem Int *88*, 124-137.
1153 Ji, Q., Castelli, L., and Goverman, J.M. (2013). MHC class I-restricted myelin epitopes are cross-
1154 presented by Tip-DCs that promote determinant spreading to CD8(+) T cells. Nat Immunol *14*,
1155 254-261.
1156 Joffre, O.P., Segura, E., Savina, A., and Amigorena, S. (2012). Cross-presentation by dendritic
1157 cells. Nat Rev Immunol *12*, 557-569.
1158 Kantoff, P.W., Higano, C.S., Shore, N.D., Berger, E.R., Small, E.J., Penson, D.F., Redfern, C.H.,
1159 Ferrari, A.C., Dreicer, R., Sims, R.B.*, et al.* (2010). Sipuleucel-T immunotherapy for castration-
1160 resistant prostate cancer. N Engl J Med *363*, 411-422.

Kaufman, J. (2018). Generalists and Specialists: A New View of How MHC Class I Molecules Fight Infectious Pathogens. Trends Immunol *39*, 367-379.

Keller, C., Mellouk, N., Danckaert, A., Simeone, R., Brosch, R., Enninga, J., and Bobard, A. (2013). Single cell measurements of vacuolar rupture caused by intracellular pathogens. J Vis Exp, e50116.

Keller, C.W., Sina, C., Kotur, M.B., Ramelli, G., Mundt, S., Quast, I., Ligeon, L.A., Weber, P., Becher, B., Munz, C., and Lunemann, J.D. (2017). ATG-dependent phagocytosis in dendritic cells drives myelin-specific CD4(+) T cell pathogenicity during CNS inflammation. Proc Natl Acad Sci U S A *114*, E11228-E11237.

Komatsu, M., Waguri, S., Ueno, T., Iwata, J., Murata, S., Tanida, I., Ezaki, J., Mizushima, N., Ohsumi, Y., Uchiyama, Y.*, et al.* (2005). Impairment of starvation-induced and constitutive autophagy in Atg7-deficient mice. J Cell Biol *169*, 425-434.

Kovacsovics-Bankowski, M., and Rock, K.L. (1995). A phagosome-to-cytosol pathway for exogenous antigens presented on MHC class I molecules. Science *267*, 243-246.

Kundu, M., Lindsten, T., Yang, C.Y., Wu, J., Zhao, F., Zhang, J., Selak, M.A., Ney, P.A., and Thompson, C.B. (2008). Ulk1 plays a critical role in the autophagic clearance of mitochondria and ribosomes during reticulocyte maturation. Blood *112*, 1493-1502.

Liao, Y., Smyth, G.K., and Shi, W. (2014). featureCounts: an efficient general purpose program for assigning sequence reads to genomic features. Bioinformatics *30*, 923-930.

Loi, M., Muller, A., Steinbach, K., Niven, J., Barreira da Silva, R., Paul, P., Ligeon, L.A., Caruso, A., Albrecht, R.A., Becker, A.C.*, et al.* (2016). Macroautophagy Proteins Control MHC Class I Levels on Dendritic Cells and Shape Anti-viral CD8(+) T Cell Responses. Cell Rep *15*, 1076-1087.

Love, M.I., Huber, W., and Anders, S. (2014). Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome biology *15*, 550.

Maranon, C., Desoutter, J.F., Hoeffel, G., Cohen, W., Hanau, D., and Hosmalin, A. (2004). Dendritic cells cross-present HIV antigens from live as well as apoptotic infected CD4+ T lymphocytes. Proc Natl Acad Sci U S A *101*, 6092-6097.

Marino, E., Tan, B., Binge, L., Mackay, C.R., and Grey, S.T. (2012). B-cell cross-presentation of autologous antigen precipitates diabetes. Diabetes *61*, 2893-2905.

Martinez, J., Almendinger, J., Oberst, A., Ness, R., Dillon, C.P., Fitzgerald, P., Hengartner, M.O., and Green, D.R. (2011a). Microtubule-associated protein 1 light chain 3 alpha (LC3)-associated phagocytosis is required for the efficient clearance of dead cells. Proceedings of the National Academy of Sciences of the United States of America *108*, 17396-17401.

Martinez, J., Almendinger, J., Oberst, A., Ness, R., Dillon, C.P., Fitzgerald, P., Hengartner, M.O., and Green, D.R. (2011b). Microtubule-associated protein 1 light chain 3 alpha (LC3)-associated phagocytosis is required for the efficient clearance of dead cells. Proc Natl Acad Sci U S A *108*, 17396-17401.

Martinez, J., Cunha, L.D., Park, S., Yang, M., Lu, Q., Orchard, R., Li, Q.Z., Yan, M., Janke, L., Guy, C.*, et al.* (2016a). Corrigendum: Noncanonical autophagy inhibits the autoinflammatory, lupus-like response to dying cells. Nature *539*, 124.

Martinez, J., Cunha, L.D., Park, S., Yang, M., Lu, Q., Orchard, R., Li, Q.Z., Yan, M., Janke, L., Guy, C.*, et al.* (2016b). Noncanonical autophagy inhibits the autoinflammatory, lupus-like response to dying cells. Nature *533*, 115-119.

Martinez, J., Malireddi, R.K., Lu, Q., Cunha, L.D., Pelletier, S., Gingras, S., Orchard, R., Guan, J.L., Tan, H., Peng, J.*, et al.* (2015). Molecular characterization of LC3-associated phagocytosis reveals distinct roles for Rubicon, NOX2 and autophagy proteins. Nat Cell Biol *17*, 893-906.

Mauthe, M., Orhon, I., Rocchi, C., Zhou, X., Luhr, M., Hijlkema, K.J., Coppes, R.P., Engedal, N., Mari, M., and Reggiori, F. (2018). Chloroquine inhibits autophagic flux by decreasing autophagosome-lysosome fusion. Autophagy *14*, 1435-1455.

1211 Nair-Gupta, P., Baccarini, A., Tung, N., Seyffer, F., Florey, O., Huang, Y., Banerjee, M.,
1212 Overholtzer, M., Roche, P.A., Tampe, R.*, et al.* (2014). TLR signals induce phagosomal MHC-I
1213 delivery from the endosomal recycling compartment to allow cross-presentation. Cell *158*, 506-
1214 521.
1215 Palmowski, M.J., Gileadi, U., Salio, M., Gallimore, A., Millrain, M., James, E., Addey, C., Scott,
1216 D., Dyson, J., Simpson, E., and Cerundolo, V. (2006). Role of immunoproteasomes in cross-
1217 presentation. J Immunol *177*, 983-990.
1218 Pooley, J.L., Heath, W.R., and Shortman, K. (2001). Cutting edge: intravenous soluble antigen is
1219 presented to CD4 T cells by CD8- dendritic cells, but cross-presented to CD8 T cells by CD8+
1220 dendritic cells. J Immunol *166*, 5327-5330.
1221 Rahimi, R.A., and Luster, A.D. (2018). Chemokines: Critical Regulators of Memory T Cell
1222 Development, Maintenance, and Function. Adv Immunol *138*, 71-98.
1223 Repnik, U., Cesen, M.H., and Turk, B. (2016). Measuring Cysteine Cathepsin Activity to Detect
1224 Lysosomal Membrane Permeabilization. Cold Spring Harb Protoc *2016*.
1225 Rock, K.L., Reits, E., and Neefjes, J. (2016). Present Yourself! By MHC Class I and MHC Class
1226 II Molecules. Trends Immunol *37*, 724-737.
1227 Rouillard, A.D., Gundersen, G.W., Fernandez, N.F., Wang, Z., Monteiro, C.D., McDermott, M.G.,
1228 and Ma'ayan, A. (2016). The harmonizome: a collection of processed datasets gathered to serve
1229 and mine knowledge about genes and proteins. Database (Oxford) *2016*.
1230 Sanchez-Paulete, A.R., Cueto, F.J., Martinez-Lopez, M., Labiano, S., Morales-Kastresana, A.,
1231 Rodriguez-Ruiz, M.E., Jure-Kunkel, M., Azpilikueta, A., Aznar, M.A., Quetglas, J.I.*, et al.* (2016).
1232 Cancer Immunotherapy with Immunomodulatory Anti-CD137 and Anti-PD-1 Monoclonal
1233 Antibodies Requires BATF3-Dependent Dendritic Cells. Cancer Discov *6*, 71-79.
1234 Sanjuan, M.A., Milasta, S., and Green, D.R. (2009). Toll-like receptor signaling in the lysosomal
1235 pathways. Immunol Rev *227*, 203-220.
1236 Saveanu, L., Carroll, O., Weimershaus, M., Guermonprez, P., Firat, E., Lindo, V., Greer, F.,
1237 Davoust, J., Kratzer, R., Keller, S.R.*, et al.* (2009). IRAP identifies an endosomal compartment
1238 required for MHC class I cross-presentation. Science *325*, 213-217.
1239 Savina, A., and Amigorena, S. (2007). Phagocytosis and antigen presentation in dendritic cells.
1240 Immunol Rev *219*, 143-156.
1241 Saxena, M., and Bhardwaj, N. (2018). Re-Emergence of Dendritic Cell Vaccines for Cancer
1242 Treatment. Trends Cancer *4*, 119-137.
1243 Schindelin, J., Arganda-Carreras, I., Frise, E., Kaynig, V., Longair, M., Pietzsch, T., Preibisch, S.,
1244 Rueden, C., Saalfeld, S., Schmid, B.*, et al.* (2012). Fiji: an open-source platform for biological-
1245 image analysis. Nat Methods *9*, 676-682.
1246 Serreze, D.V., Chapman, H.D., Varnum, D.S., Gerling, I., Leiter, E.H., and Shultz, L.D. (1997).
1247 Initiation of autoimmune diabetes in NOD/Lt mice is MHC class I-dependent. J Immunol *158*,
1248 3978-3986.
1249 Shen, L., Sigal, L.J., Boes, M., and Rock, K.L. (2004). Important role of cathepsin S in generating
1250 peptides for TAP-independent MHC class I crosspresentation in vivo. Immunity *21*, 155-165.
1251 Shvets, E., and Elazar, Z. (2009). Flow cytometric analysis of autophagy in living mammalian
1252 cells. Methods Enzymol *452*, 131-141.
1253 Snyder, A.G., Hubbard, N.W., Messmer, M.N., Kofman, S.B., Hagan, C.E., Orozco, S.L., Chiang,
1254 K., Daniels, B.P., Baker, D., and Oberst, A. (2019). Intratumoral activation of the necroptotic
1255 pathway components RIPK1 and RIPK3 potentiates antitumor immunity. Sci Immunol *4*.
1256 Stober, D., Trobonjaca, Z., Reimann, J., and Schirmbeck, R. (2002). Dendritic cells pulsed with
1257 exogenous hepatitis B surface antigen particles efficiently present epitopes to MHC class I-
1258 restricted cytotoxic T cells. Eur J Immunol *32*, 1099-1108.
1259 Turner, M.D., Nedjai, B., Hurst, T., and Pennington, D.J. (2014). Cytokines and chemokines: At
1260 the crossroads of cell signalling and inflammatory disease. Biochim Biophys Acta *1843*, 2563-
1261 2582.

1262 Wolfers, J., Lozier, A., Raposo, G., Regnault, A., Thery, C., Masurier, C., Flament, C., Pouzieux,
1263 S., Faure, F., Tursz, T., *et al.* (2001). Tumor-derived exosomes are a source of shared tumor
1264 rejection antigens for CTL cross-priming. Nat Med *7*, 297-303.
1265 Wu, S.J., Niknafs, Y.S., Kim, S.H., Oravecz-Wilson, K., Zajac, C., Toubai, T., Sun, Y., Prasad, J.,
1266 Peltier, D., Fujiwara, H., *et al.* (2017). A Critical Analysis of the Role of SNARE Protein SEC22B
1267 in Antigen Cross-Presentation. Cell Rep *19*, 2645-2656.
1268 Yatim, N., Jusforgues-Saklani, H., Orozco, S., Schulz, O., Barreira da Silva, R., Reis e Sousa, C.,
1269 Green, D.R., Oberst, A., and Albert, M.L. (2015). RIPK1 and NF-kappaB signaling in dying cells
1270 determines cross-priming of CD8(+) T cells. Science *350*, 328-334.
1271 Zhang, N., and Bevan, M.J. (2011). CD8(+) T cells: foot soldiers of the immune system. Immunity
1272 *35*, 161-168.
1273

Figure 1: *Rubcn*$^{-/-}$ DCs display enhanced cross-presentation capacity.



Figure 2: *Rubcn*$^{-/-}$ DCs engulf cargo, yet retain cargo in less degradative phagosomes.



Figure 3: *Rubcn*$^{-/-}$ DCs exhibit increased phagosome-to-cytosol escape and proteasome-mediated generation of peptides



Figure 4: *Cd11c-Cre Rubcn*$^{flox/flox}$ mice display decreased tumor burden and increased antigen-specific CD8$^+$ T cell activation.



Figure S1, related to Figure 1: *Rubcn*$^{-/-}$ DCs display increased cross-presentation capacity but equivalent levels of peptide-mediated MHCI antigen presentation.



Figure S2, related to Figure 1: Defects in LAP, not canonical autophagy, result in increased cross-presentation



Figure S3, related to Figures 2 and 3: *Rubcn*$^{-/-}$ DCs display increased phagosome-to-cytosol antigen escape and sensitivity to proteasome inhibition.



Figure S4, related to Figure 4: *Cd11c-Cre⁺ Rubcn$^{flox/flox}$* mice DCs display increased anti-tumor immunity at day 22 *in vivo*.



STAR METHODS

KEY RESOURCES TABLE

REAGENT or RESOURCE
Antibodies
Horseradish Peroxidase AffiniPure Goat Anti-Rabbit IgG (H+L)
TruStain FcX™ (anti-mouse CD16/32) Antibody, Clone: 93
Goat Anti-mouse AlexaFluor-555
Anti-Mouse LAMP2 APC, Clone: M3/84
Anti-RAB5A FITC
Anti-Mouse Sec22b, Clone: 29-F7
Anti-RUBCN, Clone:D9F7
Anti-Actin, Clone: I-19
Anti-Mouse CD103 PE/Dazzle™ 594, Clone:2E7
Anti-Mouse CD45 BV605, Clone:30-F11
Anti-Mouse CD8 PE dazzle, Clone:53-6.7
Anti-Mouse CD3 PerCP/Cy5.5, Clone: 17A2
Anti-Calreticulin AlexaFluor-488
Anti-Mouse CD11c BV421, Clone:N418
Anti-Mouse CD11b PE/Cy5, Clone: M1/70
Anti-Mouse F4/80 APC/Cy7, Clone: BM8
Anti-Mouse CD69 APC, Clone: H1.2F3
Anti-Mouse CD86 PerCP/Cy5.5, Clone:GL-1
Anti-Mouse Perforin APC, Clone: S16009B
Anti-Mouse Granzyme B Pacific Blue™, Clone: GB11
Anti-Mouse TNFα PE, Clone: MP6-XT22
Anti-Mouse H-2Kb bound to SIINFEKL PE/Cy7, Clone: 25-D1.16
Anti-Mouse H-2Kb APC, Clone: AF6-88.5
Anti-Mouse IFN-γ BV510, Clone: XMG1.2
Anti-Mouse CD11b APC, Clone: N418
Anti-mouse H-2Kb-$OVA_{257-264}$ tetramer
Purified anti-mouse CD86 antibody, Clone: PO3
Purified rat IgG2b, κ isotype control antibody, Clone: RTK4530
Chemicals, Peptides, and Recombinant Proteins
Polystyrene beads (3 micron)
OVA257-264 peptide
Low endotoxin whole ovalbumin
Ovalbumin, Alexa Fluor™ 555 Conjugate
PKH26 Red Fluorescent Cell Linker Kit for General Cell Membrane Labeling
HBSS, no calcium, no magnesium, no phenol red
RPMI 1640 Medium
HEPES
Glutamax
0.5 M EDTA, pH 8.0
PBS
Fetal Calf Serum (FCS)
Penicillin-Streptomycin
2-mercaptoethanol
DMEM
Geneticin
Percoll
Z-FR-AMC
IgG-Free, Protease-Free Bovine Serum Albumin (BSA)
Collagenase D
Accutase
Collagenase XI
Hyaluronidase type I-S
CCF4
β-lactamase
Probenecid
Chloroquine

MG-132
DNase I
4% fixative Image-iT™
Triton X-100
Poly-D-Lysine
DTT
UltraPure™ DNase/RNase-Free Distilled Water
Digitonin
Sodium azide
Brefeldin A Solution (1000X)
Phorbol 12-myristate 13-acetate (PMA)
Ionomycin
Recombinant FMS-like tyrosine kinase-3 ligand (rFlt3L)
Amonnia Chloride Solution

Critical Commercial Assays

RNeasy Plus Mini Kit
TRIzol™
EasySep™ Mouse CD8+ T Cell Isolation Kit
Mouse Pan-DC Enrichment Kit
Medium wave UV lamp, 312nm
TaqMan™ Universal PCR Master Mix
Fixation/Permeabilization Solution Kit
LEGEND MAX™ Mouse IFN-β ELISA Kit
Bio-Plex Pro™ Mouse Cytokine 23-plex Assay
Tag-it violet Dye
Zombie UV™ Fixable Viability Kit
pHrodo Red Microscale Labeling Kit

Experimental Models: Organisms/Strains

Mouse: 129S4/SvJaeSor-*Gt(ROSA)26Sor*$^{tm1(FLP1)Dym}$/J , ROSA26::FLPe knock in
Mouse: B6.Cg-Tg(Itgax-cre)1-1Reiz/J, *CD11cCre*^{T} , *Cd11c-Cre*
Mouse: B6.Cg-Atg7$^{tm1.1Tchi}$, C57BL/6-Atg7$^{flox/flox}$
Mouse: *Atg7*$^{flox/flox}$ *CD11c-Cre*$^{+}$
Mouse: *Rubicon*$^{-/-}$,C57BL/6-*Rubcn*^{em1Dgre}*/J, Rubcn*$^{-/-}$
Mouse: Rubcn$^{flox/flox}$,*B6-Rubcn*$^{tm1a(EUCOMM)Wtsii}$
Mouse: *CD11c-Cre*$^{+}$ *Rubcn*$^{flox/flox}$
Mouse: B6.129-*Ulk1*^{tm1Thsn}/J, Ulk1$^{+/+}$, *Ulk1*$^{-/-}$
Mouse: *C57BL/6-Tg(TcraTcrb)1100Mjb/J* (OT-1 B6)

Cell lines

B16-OVA cells
Jurkat cells

qPCR probes

Gene: *Tap1* , Dye: FAM-MGB
Gene: *Tap2* , Dye: FAM-MGB
Gene: *B2m*, Dye: FAM-MGB
Gene: *Rubicon* , Dye: FAM-MGB
Gene: *Actinb* , Dye: VIC-MGB

Software and Algorithms

FlowJo (v.10)
Prism v.7.0c
Zen Blue
BD FACS Diva 8

Partek

Ingenuity Pathway Analysis software
Fiji

References

Komatsu, M., et al., Impairment of starvation-induced and constitutive autophagy in Atg7-deficient mice. J Cell Biol, 2005. 169(3): p
Kundu, M., et al., Ulk1 plays a critical role in the autophagic clearance of mitochondria and ribosomes during reticulocyte maturation
Martinez, J., et al., Molecular characterization of LC3-associated phagocytosis reveals distinct roles for Rubicon, NOX2 and autophag
Martinez, J., et al., Noncanonical autophagy inhibits the autoinflammatory, lupus-like response to dying cells. Nature, 2016. 533(760

SOURCE	IDENTIFIER
Jackson ImmunoReseach Laboratories, INC.	Cat#: 111-035-144, RRID:AB_2307391
Biolegend	Cat #:101319 RRID:AB 1574973
Thermo-Fisher Scientific	Cat #:21424, RRID:AB 141780
Biolegend	Cat #: 108506, RRID: AB 313387
Abcam	Cat #:ab183454, RRID:N/A
Santa Cruz Biotechnology	Cat #: sc-101267; RRID:AB 2186088
Cell Signaling	Cat#: 8465; RRID:AB 10891617
Santa Cruz Biotechnology	Cat#: sc-1616, RRID:AB 630836
Biolegend	Cat #: 121429; RRID: AB 2566492
Biolegend	Cat #:103139; RRID:AB 2562341
Biolegend	Cat #:100761; RRID:AB 2564026
Biolegend	Cat #:100217; RRID:AB 1595597
Abcam	Cat #:ab196158; RRID:N/A
Biolegend	Cat #:117343; RRID:AB 2563099
Biolegend	Cat #:101209; RRID:AB 312792
Biolegend	Cat #:123117; RRID:AB 893489
Biolegend	Cat #:104514; RRID:AB 492843
Biolegend	Cat #:105028, RRID: AB 2074994
Biolegend	Cat #:154404 RRID:AB 2721465
Biolegend	Cat #:515408 ; RRID:AB_2562196
Biolegend	Cat #:506306; RRID:AB 315427
Biolegend	Cat #: 141608; RRID:AB 11218593
Biolegend	Cat #: 116518; RRID:AB 10564404
Biolegend	Cat #:505841; RRID:AB 2562187
Biolegend	Cat #:117310 ; RRID:AB 313779
NIH Tetramer Core Facility	N/A
Biolegend	Cat #: 105102, RRID:AB 313155
Biolegend	Cat #: 400602, RRID: AB 326546

Polysciences	Cat#: 17134
Invivogen	Cat#: vac-sin
Worthington Biochemical	Cat#: LS003061
Life Technologies/ Thermo Fisher Scientific	Cat#: O34782
Sigma-Aldrich	Cat#:PKH26GL-1KT
Life Technologies/ Thermo Fisher Scientific	Cat#:14175095
Life Technologies/ Thermo Fisher Scientific	Cat#:11875093
Life Technologies/ Thermo Fisher Scientific	Cat#:15630080
Life Technologies/ Thermo Fisher Scientific	Cat#: 35050061
Gibco	Cat #:15575-038
Gibco	Cat#:10010023
HyClone	Cat#:SH3007303
Life Technologies/ Thermo Fisher Scientific	Cat#: 15140122
Life Technologies/ Thermo Fisher Scientific	Cat#: 21985023
Life Technologies/ Thermo Fisher Scientific	Cat#: 11965118
Life Technologies/ Thermo Fisher Scientific	Cat#: 10131027
GE Healthcare	Cat#: 17089101
AnaSpec	Cat#:AS-24096
Jackson ImmunoReseach Laboratories, INC.	Cat#:001-000-162
Roche	Cat#: 11088858001
Life Technologies/ Thermo Fisher Scientific	Cat#:A1110501
Sigma-Aldrich	Cat#:C7657-25MG
Sigma-Aldrich	Cat#:H3506-100MG
Life Technologies/ Thermo Fisher Scientific	Cat#: K1030
Sigma-Aldrich	Cat#: L6170
Sigma-Aldrich	Cat#: P8761
Sigma-Aldrich	Cat#: C6628

Sigma-Aldrich	Cat#: 474790
Roche	Cat#:3724778103
Life Technologies/ Thermo Fisher Scientific	Cat#:R37814
Sigma-Aldrich	Cat#:X100
Sigma-Aldrich	Cat#:P4832
Sigma-Aldrich	Cat#:DTT-RO
Life Technologies/ Thermo Fisher Scientific	Cat#:10977015
Sigma-Aldrich	Cat#:D141
Sigma-Aldrich	Cat#: S2002
Life Technologies/ Thermo Fisher Scientific	Cat#:00-4506-51
Sigma-Aldrich	Cat#:P8139
Sigma-Aldrich	Cat#:I0634
NIEHS Protein Expression Core	N/A
STEMCELL techonologies	Cat#: 07800

QIAGEN	Cat#:74134
Life Technologies/ Thermo Fisher Scientific	Cat#:15596026
STEMCELL techonologies	Cat#:19853
STEMCELL techonologies	Cat#: 19763
Spectroline	Cat#: 1981172 csa22.2 No. 1010-1
Life Technologies/ Thermo Fisher Scientific	Cat#:4364338
Becton Dickinson	Cat#:554714
Biolegend	Cat#: 439407
Bio-Rad	Cat#: M60009RDPD
Biolegend	Cat #:425101
Biolegend	Cat #:423107
Life Technologies/ Thermo Fisher Scientific	Cat#: P35363

JAX	Strain #: 3946
JAX	Strain #:008068
Komatsu M, *et al,.* 2005/ RIKEN BRC	Strain #:RBRC02759
Martinez *et al.,* 2016	N/A
Martinez *et al.*, 2015 /JAX	Strain #:032581
This manuscript	N/A
This manuscript	N/A
Kundu *et al.,* 2008, JAX	Strain #:17976
JAX	Stain#: 003831

University of Washington (Oberst lab)	N/A
NIEHS (Fessler lab)	N/A

Life Technologies/ Thermo Fisher Scientific	Cat# 4448892, Assay ID#: Mm00443188_m1
Life Technologies/ Thermo Fisher Scientific	Cat# 4331182, Assay ID#: Mm01277033_m1
Life Technologies/ Thermo Fisher Scientific	Cat#4331182, Assay ID#: Mm00437762_m1
Life Technologies/ Thermo Fisher Scientific	Cat#4351372, Assay ID#: Mm01170688_g1
Life Technologies/ Thermo Fisher Scientific	Cat#4448489, Assay ID#: Mm02619580_g1

TreeStar	https://www.flowjo.com/solutions/flowjo/downloads
Graph Pad	https://www.graphpad.com/demos
Zeiss	https://www.zeiss.com/microscopy/us/products/micros
BD Biosciences	http://www.bdbiosciences.com/us/instruments/clinical/software/flowcytometry-acquisition/bd-facsdivasoftware/m/333333/overview
Partek genomics suite software	http://www.partek.com/partek-genomics-suite/

Qiagen	https://www.qiagenbioinformatics.com/products/inger
Image J	https://imagej.net/Fiji/Downloads

. 425-34.
. Blood, 2008. 112(4): p. 1493-502.
y proteins. Nat Cell Biol, 2015. 17(7): p. 893-906.
)1): p. 115-9.

:cope-software/zen.html

uity-pathway-analysis/